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This 25th International Symposium on Infections in the Critically Ill Patient aims to review 
current concepts, technology and present advances in infections in critically ill patient. Sepsis, 
Pulmonary Infections and their therapeutic and preventive strategies will be the topics presented by 
international experts who will review and update sepsis as a global international problem. 
New guidelines epidemiological information on sepsis, fluid therapy and vasopressors, a 
personalize sepsis care and new therapies and future randomized control trials are provided. The 
immune response and the emerging methods to personalize sepsis care including new biomarkers, 
sepsis phenotypes and end types and immunomonitoring of patients with sepsis represent a new 
complementary view to treat patients with severe infections and organ failure in addition to early 
antibiotic and the control of source of infection. New insights of cell therapies and extracorporeal 
treatment will be provided. 
The preliminary information about the European severe community pneumonia guidelines and 
new diagnostic approaches for nosocomial pulmonary infections, new antibiotics and the 
optimization of their use represent key factors to improve outcome and prevention of severe 
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2.1. SESION I. SEPSIS
2.1.1. How 25 Years of Research Has Changed My Practice in Sepsis?
Jean-Louis Vincent
Dept of Intensive care, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium
Despite decades of sepsis research, no specific immunomodulatory sepsis therapies are currently
available, except perhaps corticosteroids, so from that point of view, research has not changed my
clinical practice very much. However, research and changes in other aspects of patient management
and process of care have certainly influenced the way I treat my patients with sepsis. There are perhaps
three key areas that have altered over the years:
1. One of the most important realizations has been the importance of the time factor when
managing patients with sepsis −time is tissue. Making a rapid diagnosis and starting appropriate
treatment promptly are keys to limiting organ dysfunction and maximizing patient outcomes. Increased
awareness of sepsis in the ICU but also in other hospital departments and before hospital admission is
helping identify patients earlier so that appropriate monitoring, investigations and treatment can be
started. Rapid response teams that can attend patients with suspected sepsis on the general ward are
now present in many hospitals. The need for adequate, rapid resuscitation has also been highlighted
and increasingly fluids and vasopressors are started simultaneously rather than waiting to see what
effect may fluid has before vasoactive agents are introduced. Any period of hypotension can be
harmful, and it is better to start these two branches of resuscitation together to restore a minimum
perfusion pressure as soon as possible. Vasopressor agents can then be weaned once the patient’s
hemodynamic status is optimized. An important research result in the last 25 years was the finding that
norepinephrine should be used in preference to dopamine as the first-line vasopressor. The importance
of removal of excess fluid once the patient has stabilized has also come to the fore with persistent
positive fluid balance associated with worse outcomes. My management of the patient with sepsis is
thus guided by the SOSD paradigm: salvage, optimization, stabilization, de-escalation. I use changes
in blood lactate levels over time to provide an indication of response to treatment, with increasing or
stable levels suggesting diagnosis and/or treatment needs to be reviewed and possibly altered.
2. Another area where practice has changed is that we have become much less invasive.
Echography is much more widely available and practiced routinely at the bedside in many units for
initial hemodynamic assessment and diagnosis of associated cardiac conditions. The pulmonary artery
catheter still has a place in severely ill, complex patients but non-invasive techniques have replaced it
in some patients. The move towards less-invasive monitoring is set to continue as technology advances
and devices become smaller, more effective and efficient, and more available.
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3. A third area, the need to personalize therapies, has also been stressed in recent years and is
reflected in using fewer one-size-fits-all targets and adapting treatments according to the characteristics
and needs of individual patients. As just one example, a target mean arterial pressure of 65 mmHg
may be appropriate for many patients, but a patient with chronic hypertension may benefit from a
higher target, and in a younger patient with no evidence of arteriosclerosis, a lower pressure may be
adequate. Similarly, blood transfusions should not be given based only on a hemoglobin concentration
but the pros and cons weighed up in each patient, taken into consideration age, disease severity, and a
history of cardiac ischemia among others.
As we become more able to characterize the sepsis response in individual patients, we will be
better able to select patients for inclusion in clinical trials according to their likelihood to respond to
treatment rather than testing all agents in heterogeneous groups as was the rule until recently. This
will result in more trial interventions demonstrating a beneficial effect on survival and I am confident
that within the next 25 years, I will be including personalized immunomodulatory therapies in the
management of my patients with sepsis.
Suggested reading
• Vincent JL (2018) How I treat septic shock. Intensive Care Med 44:2242–2244.
• Annane D, Renault A, Brun-Buisson C, et al. (2018) Hydrocortisone plus fludrocortisone for adults
with septic shock. N Engl J Med 378:809–818
• Rhodes A, Evans LE, Alhazzani W et al. (2017) Surviving Sepsis Campaign: International
Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45:486–552.
• De Backer D, Aldecoa C, Njimi H et al. (2012) Dopamine versus norepinephrine in the treatment
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2.1.2. Are Sepsis Outcomes Predetermined
Ricard Ferrer
Intensive Care Medicine Department, Vall d’Hebron University Hospital, Barcelona and Spain
Abstract: Along with the control of source of infection and adequate hemodynamic resuscitation,
the administration of an early appropriate antimicrobial treatment is the single the most important
available means to face the adverse prognosis associated with sepsis. Sepsis is a medical emergency
and time-dependent condition due to a dysregulated host response to infection, which is associated
with multi-organ dysfunction and unacceptably high odds for mortality. Based on this premise,
when treating patients with possible or confirmed sepsis, clinicians must initiate broad-spectrum
antimicrobials as soon as possible, preferably within the first hour of diagnosis, as recommended by
the 2016 SSC guidelines. Different scientific societies give support for the importance of timing, as
several studies have demonstrated the benefits of the early initiation of appropriate antibiotic therapy,
particularly in patients with septic shock. Accordingly, there are many well-performed studies on
the effects of delayed administration of antibiotics in patients with sepsis and septic shock. Delayed
administration of antibiotics has been also associated with increased hospital length of stay, higher
rates of acute lung injury and acute kidney injury, and worsening organ dysfunction. However, the
effective application of institutional protocols to improve the administering antimicrobials within 1 h
from presentation remains challenging. Availability of antimicrobials, general disbeliefs regarding
the severity of sepsis and inappropriate local policies are some barriers to implement suitable goals.
As medical decisions rely on clinical judgment, when facing a patient presenting with a non-severe
infection or an alternative diagnosis is being considered, additional diagnostic data should be obtained
before administering broad-spectrum antibiotics. Optimizing antimicrobial therapy is essential to
reduce mortality and the emergence of multi-drug resistant pathogens. The routine assessment of the
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previous risk for multi-drug resistant pathogens prior to the early administration of antimicrobials
should be performed in all patients. Procalcitonin-based approaches have been demonstrated to
be useful to guide treatment in most patients with sepsis and septic shock. Compliance to practice
guidelines, optimization and continuous assessment of duration and appropriateness of antimicrobials
are essential components of any antimicrobial stewardship program. De-escalation and shortened
courses of antimicrobials are also key components of such programs.
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2.1.3. We Must Act Before the Hospital Admission
Herwig Gerlach
Dept. for Anesthesia, Intensive Care, Medicine and Pain Management Vivantes—Klinikum Neukoelln,
Rudower Strasse 48, D-12351 Berlin, Germany
“Hectic fever at its inception is difficult to recognize but easy to treat; left untended, it becomes easy
to recognize but difficult to treat.” This historical citation from Niccolò Machiavelli around 1513 AC [1]
seems very simple but contains a lot of hints leading to issues which are part of current discussions
about (very) early treatment of sepsis and septic shock. Looking back, the structured research on
the ideal timepoint of sepsis treatment began in 2004, when the Surviving Sepsis Campaign (SSC)
published the first international guidelines on the management of sepsis. Meanwhile, the 4th version
of the SSC guidelines are available, and several recommendations contain a defined timepoint [2].
Based on the initial guidelines, the SSC launched a prospective project testing so called “Sepsis
Bundles”, which are a condensed form of some (not all) recommendations from the guidelines. One of
these bundles (called “Sepsis Resuscitation Bundle”) has a time frame of 6 h after identifying severe
sepsis or septic shock; the second (called “Sepsis Management Bundle”) was limited to 24 h. In 2010,
the data from this project were published [3]; it was demonstrated that several treatment options had a
clear time-dependent effect, one of which was the early application of antibiotics. In contrast, other
treatments failed to show a benefit. Hence, the SSC bundles were reviewed, resulting in a single bundle
containing early treatments with a time frame of 3 or 6 h. Based on a political action, this bundle was
initiated as a mandatory rule for hospitals in several states of the USA.
In 2017, the electronic hospitals records for these states were evaluated regarding the effect of the
sepsis bundle on the outcome of included patients [4]. The data revealed a time-dependent survival
benefit of early administration of antibiotics, early measurement of lactate, as well as early blood
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cultures in septic patients. All three options demonstrated their positive effect continuously over time
and from the first hour after sepsis detection. This led the SSC to revise the bundles again, which
resulted in the recent SSC Bundles 2018 [5]; based on the aforementioned results, the time frame was
now set to 60 min for the treatment options 1) blood cultures, 2) lactate measurement, 3) application of
broad-spectrum antibiotics, 4) fluid bolus in patients with hypotension or lactate > 4 mmol/L, and 5)
administration of vasopressors after the fluid bolus if hypotension is still present to maintain a mean
arterial pressure of ≥65 mmHg [5]. Briefly after the aforementioned 1-h bundle was published, there
was a huge discussion, partially by internet-based petitions, and finally it was decided to put the new
1-h bundle “on hold”.
The discussions, which are still ongoing, are partially very puzzling. One major issue is the
early administration of broad-spectrum antibiotics, which is questioned especially by infectiologists,
who express their worry about unneeded treatment in patients without the final diagnosis of sepsis.
Moreover, they claim that the 1-h bundle may lead to more antibiotics use in total, which is definitely
against the current trend to stop the overuse of antibiotics in hospitals. A recent Pro-Con-debate tried
to find a compromise but finally failed to do so [6,7]: The Authors “Pro Early Antibiotics” cited several
studies including the aforementioned paper by Seymour et al. [4], which together provide a very
convincing picture on the obvious benefit of early antibiotics even within one hour in patients with
sepsis or septic shock. Unfortunately, the Authors “Con Early Antibiotics” did not challenge these
facts but concentrated completely on the terms “appropriate” and “broad-spectrum” for antibiotics.
One argument in this context is, that these two descriptors are not synonymous, and that appropriate
empiric therapy should consist of targeted antibiosis that considers the unique factors and context of
the patient [7]. This leads back to the initial citation of Machiavelli from the 16th century: without clear
recognition of “unique factors” and “context of the patient”, which is a synonym for an unambiguous
diagnosis, no treatment or treatment that is too late?! But this is exactly the wrong way! We have
to accept that we are simply not able to make a clear diagnosis in the very early phase of sepsis
management, and that this sensitive phase is the optimal time point for effective antibiosis.
Finally, what is with the prehospital setting? Data are very limited, and there are some ongoing
studies to evaluate the effect of treatment bundles in this phase. Most of these studies concentrate on the
recognition of patients, which is the key issue in the very early phase of sepsis, as we discussed already
above. In a small study in mobile emergency units, a point-of-care lactate assay was used together
with several simple clinical parameters [8]. As a promising result, the Authors found that around half
of those patients, who were later identified a sepsis cases, were already recognized in the prehospital
setting, and moreover, that the final hospital mortality of the patients, in whom the algorithm was
applied, was significantly lower compared with patients receiving standard management. A recent
review tried to put together the literature and finally stated that (1) recognition of sepsis by ambulance
clinicians is poor, (2) the use of screening tools, based on the SSC diagnostic criteria, improves
prehospital sepsis recognition, and (3) screening tools derived from EMS data have been developed,
but they have not yet been validated in clinical practice [9].
In conclusion, there currently is an open discussion on the ideal time point of early treatment,
especially regarding administration of empiric antibiotics when no clear diagnosis is available. But, on
the other hand, we must ask: what are we waiting for? Why should 3 h waiting time be better than
1 h? There will be no result from the blood cultures or from any other microbiological sample. For the
prehospital setting, it must be admitted that we cannot have a clear diagnosis of sepsis as defined by
current definitions since several parameters of the SOFA score are not available. Reason enough to
foster clinical studies in this context!
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2.2. SESION II. FLUID THERAPY AND VASSOPRESSORS
2.2.1. Use of Vasopressors in Septic Shock
Olfa Hamzaoui
ICU, Beclere University Hospital, Clamart, France
In spite of multiple therapeutic advances over the past decades, septic shock remains the leading
cause of morbidity and mortality in critically ill patients [1].
Why to Use Vasopressors in Septic Shock?
Besides relative and absolute hypovolemia, depressed vascular tone is a major characteristic of
septic shock, mostly due to excessive release of inflammatory mediators. Vascular tone depression must
lead to severe hypotension, which may induce hypoperfusion of vital organs if mean arterial pressure
(MAP) decreased below a certain critical level [2]. In this regard, correction of severe hypotension with
vasopressors can improve regional blood flows as suggested by studies showing an improvement in
urine flow [3,4] and creatinine clearance [4] with increased MAP but unchanged cardiac output.
Which First-Line Vasopressor?
There is nowadays a consensus to recommend norepinephrine as the fist-line vasopressor in septic
shock [5,6]. This recommendation is supported by a meta-analysis that clearly showed the superiority
of norepinephrine over dopamine [7].
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When to Start the Vasopressor?
In the past, the vasopressor therapy was started after complete correction of hypovolemia.
Nowadays, the vasopressor—namely norepinephrine—is most often initiated earlier [6]. There are
several arguments that support this therapeutic strategy:
(1) Early initiation of norepinephrine can prevent prolonged and severe hypotension. Severe and prolonged
hypotension is associated with a poor outcome in septic shock [8]. In presence of depressed arterial
tone, fluid administration alone cannot restore a sufficient MAP. Early administration of norepinephrine
can thus shorten the duration of severe.
(2) Early initiation of norepinephrine can increase cardiac output through an increase in cardiac preload.
Due to its α1-adrenergic properties, norepinephrine is able to redistribute blood from unstressed to
stressed volume [9] and thus to increase cardiac preload. As septic patients are most often preload
responsive at the early phase, norepinephrine can thus increase cardiac output when administered
early [10].
(3) Early initiation of norepinephrine can also increase cardiac output through an increase in cardiac
contractility. Due to its β1-adrenergic properties, norepinephrine is able to enhance contractility as
recently demonstrated [11]. This effect should occur at the early phase of sepsis, as the β1-adrenergic
receptors are not yet downregulated. In addition, as norepinephrine increases vascular tone, it increases
the diastolic arterial pressure (DAP) and thus prevent or correct left ventricular myocardial ischemia
in predisposed patients (especially those with prior coronary artery disease), what can also improve
cardiac contractility.
(4) Early initiation of norepinephrine results in less fluid requirements [12] and should prevent
harmful fluid overload.
(5) Early initiation of norepinephrine should eventually improve outcome as suggested by a recent
randomized placebo-controlled clinical trial [13].
A simple way to identify patients who need urgent initiation of norepinephrine is the presence of
a low DAP, which generally reflects a low arterial tone [14].
What Is the Optimal Blood Pressure to Target?
There is no universally admitted MAP threshold ensuring that blood flow is independent of arterial
pressure in most vital organs. Nevertheless, in septic shock, current resuscitation guidelines recommend
to achieve and maintain MAP ≥ 65 mmHg, in order to avoid additional organ hypoperfusion [5,6].
Patients with prior hypertension are supposed to have a rightward shift of the autoregulation curve
(organ blood flow vs. organ perfusion pressure). This should result in a higher MAP to target in this
subpopulation of patients as suggested by a randomized controlled trial that showed benefits in renal
function when septic shock patients with chronic hypertension are managed with a higher MAP target
(80–85 mmHg vs. 65–70 mmHg) [15].
What to Do in Cases of Refractory Hypertension?
There is no consensual definition of refractory hypertension. For some experts (but not all), it
is defined by inability of 1 µg/kg/min norepinephrine to reach 65 mmHg MAP. It is noteworthy that
some studies like that by Auchet et al. showed that even for doses far higher than 1 µg/kg/min, 40% of
patients with septic shock can be discharged alive [16]. Nevertheless, current guidelines recommend
adding vasopressin to reach the MAP target or to reduce the norepinephrine dosage. Note that recent
randomized controlled trial did not find any benefits in adding vasopressin to norepinephrine [17–19]
so that the question is still open. Adding Angiotensin II to norepinephrine is not recommended,
although there is data showing that the former agent can reduce the dosage of the latter [20], which
would theoretically result in less harmful effects of norepinephrine. Maybe the future is to combine
norepinephrine, vasopressin and angiotensin II at low doses not as a rescue therapy but at the
beginning of resuscitation [21]. Finally, in cases of escalating doses of norepinephrine, administration
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of hemisuccinate of hydrocortisone is a reasonable option [5,6] with the aim of accelerating shock
resolution [22,23] and eventually improving outcome [23].
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2.2.2. Albumin Fluid Resuscitation in Patients with Septic Shock
Antonio Artigas
Critical Care Center, Corporació Sanitaria Universitaria Parc Tauli, CIBER Enfermedades Respiratorias,
Autonomous University of Barcelona, Spain
Fluid administration is often the first line treatment in patients with sepsis and septic shock,
but both too much and too little fluid can negatively impact on patients outcome.In cases of “fluid
unresponsiveness”, fluid can only exert some deleterious effects.It is now well demonstrated that
excessive fluid administration is harmful especially during sepsis and septic shock [1–4]. Then,
predicting whether volume expansion will result in the expected increase in cardiac output is one
of daily challenges when treating such patients.Recent studies have improved our evidence-base
regarding the different fluids available, but each solution has a specific profile and choices must be
guided by individual patient characteristics [5].
Colloid solutions remain longer in intravascular space thus are less likely to cause edema, and
should considered in combination with crystalloids and vasopressors, especially in patients likely to
require large fluid volumes and in patients with sepsis and acute lung injury [6,7]. The only natural
colloid is human albumin, which may have beneficial effects in patients with sepsis. In addition to
its effects on volume expansion, albumin transport sphingosin-1-phosphate which has protective
endothelial effects, acts as a free radical scavenger, and has immunomodulatory and anti-inflammatory
effects. Plasma protein such albumin is physiologically bound within the glicocalix, thus contributing
to stability of the layer [8,9].
Low serum albumin concentration has been reported in 30% to 50% of critically ill patients
associated with a higher mortality rates. Therefore, the potential benefit of albumin administration
in patients with sepsis has been tested in different clinical trials (CT). Randomized CTs comparing
albumin to crystalloids resuscitation fluids found no overall differences, however a consistent effect
has been observed in subgroups of patients with septic shock with a decreased in mortality rate and a
greater catecolamine free days [10]. Patients with septic shock and hypoalbuminemia may represent
the most suitable target population [11]. Several ongoing CTs may provide additional evidence and
the role of the additional physiologic effects of albumin.
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2.2.3. Arguments for an Early Administration of Norepinephrine in Septic Shock
Jean-Louis Teboul
Medical ICU, Bicetre University Hospital, Paris-Saclay University, Le Kremlin-Bicêtre, France
Introduction
Decreased vascular tone is a hallmark of septic shock and contributes much to the severity of
sepsis-induced hypotension. Physiologically, organ blood flow depends on perfusion pressure when
mean arterial pressure decreases below a certain critical value. It is thus important to correct severe
hypotension as early as possible and not to delay the initiation of vasopressors, even before completion
of fluid resuscitation [1]. Norepinephrine is recommended as the first-line vasopressor in septic
shock [2]. There are many important arguments that support the recommendation from a group of
34 experts—all members of the European Society of Intensive Care Medicine [1]—in favor of early
administration of norepinephrine in septic shock.
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Arguments Supporting Early Initiation of Norepinephrine
(1). Early initiation of norepinephrine can prevent prolonged and severe hypotension
Not only the degree but also the duration of hypotension is associated with poor outcome in
septic shock [3]. In presence of depressed arterial tone, fluid administration alone is not enough to
correct severe hypotension and can even potentially decrease vascular tone [4]. Early initiation of a
powerful vasopressor such as norepinephrine—in combination with fluid therapy—can thus shorten
the duration of hypotension in comparison with fluid alone.
(2). Early initiation of norepinephrine increases cardiac output in septic shock
Many studies showed that norepinephrine increases cardiac output when initiated early in patients
with septic shock [5]. In a study that included 105 severely hypotensive patients, the increase in cardiac
output with norepinephrine was associated with an increase in cardiac preload and a reduction in
pulse pressure variation [6]. Such results suggest that norepinephrine through its α1-adrenergic effects
is able to redistribute venous blood from the unstressed to the stressed blood volume as confirmed
by a study that reported an increase in mean systemic filling pressure with norepinephrine [7]. Since
septic patients are most often preload responsive at the early phase, the increase in cardiac preload
can thus increase cardiac output. Moreover, norepinephrine through β1-adrenergic stimulation may
increase left and right ventricular contractility when administered early as suggested by results of a
recent clinical study where norepinephrine was initiated in the first three hours of resuscitation [8].
(3). Early initiation of norepinephrine may improve microcirculation in septic shock
In severely hypotensive patients, restoration of organ perfusion pressure with norepinephrine
may result in improved microcirculatory blood flow as suggested by a study using near-infrared
spectroscopy at the level of the thenar eminence in patients with septic shock [9].
(4). Early initiation of norepinephrine prevents harmful fluid overload
Positive fluid balance is independently associated with increased mortality in septic shock [10].
As norepinephrine also increases cardiac preload and cardiac output, its early initiation should reduce
the volume of infused fluids. In a retrospective study in patients with septic shock, patients in whom
norepinephrine was started within the first two hours of resuscitation received fewer fluids than those
who received a delayed norepinephrine administration [11].
(5). Early initiation of norepinephrine might improve outcome
In a cohort of 213 patients with septic shock, the time to initiate norepinephrine was reported to
be an independent factor associated with mortality [11]. Interestingly, in the subgroup of patients who
received norepinephrine within the first two hours of resuscitation, the duration of administration of
norepinephrine was shorter while the total dose of norepinephrine was lower than in the subgroup of
patients in whom initiation of norepinephrine was delayed [11]. Recently, a randomized controlled trial
compared two strategies of norepinephrine initiation: early initiation (n = 155) vs. delayed initiation
(n = 155). The primary outcome was shock control rate by six hours after diagnosis. The shock
control was defined as: (1) mean arterial pressure of at least 65 mmHg and (2) either urine output
≥0.5 mL/kg/h for 2 consecutive hours or a decrease in lactate ≥10% from baseline. Shock was controlled
in significantly more patients in the early norepinephrine initiation arm compared to the delayed
norepinephrine initiation arm [12]. In addition, there were lower rates of cardiogenic pulmonary
edema and of new episodes of cardiac arrhythmia in the early vs. delayed norepinephrine initiation.
These findings clearly support the benefit of early initiation of norepinephrine in septic shock.
Identification of Patients Who Need Urgent Initiation of Norepinephrine
In patients with sepsis-induced hypotension, norepinephrine should be initiated when the vascular
tone depression is judged to contribute significantly to hypotension. As the diastolic arterial blood
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pressure (DAP) reflects the vascular tone, a low DAP (e.g., <40 mmHg) is strongly suggestive of a
markedly depressed arterial tone and should prompt initiation of norepinephrine urgently [13].
Conclusions
Early administration of norepinephrine during septic shock may benefit to patients through
an increase in cardiac output, due to an increase in cardiac preload and in cardiac contractility,
an improvement of microcirculation and a limitation of fluid overload. Recent data suggest that
early administration of norepinephrine may improve outcome. In the case of any doubt, the clinician
should look at the DAP, a marker of vascular tone. A low DAP can simply identify patients who need
norepinephrine urgently.
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2.2.4. Early vs. Delayed Norepinephrine Administration in Septic Shock? No
Daniel De Backer
Department of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium
Patients with septic shock require the combined administration of fluids and vasopressors.
Septic shock is defined as “a subset of sepsis in which profound circulatory, cellular and metabolic
abnormalities are associated with a greater risk of mortality than in sepsis alone” (1). It is best identified
as “hypotension requiring use of vasopressors to maintain a mean blood pressure of 65 mmHg or greater
and having a serum lactate level greater than 2 mmol/L persisting after adequate fluid resuscitation”
(2). Apparently, this may imply that shock require vasopressor per definition, so that the debate would
be useless. However other definitions importantly state that shock is a life-threatening form of acute
circulatory failure associated with inadequate oxygen utilization, a condition in which hypotension is
not a prerequisite (3). Hence the definitions highlight the role of tissue perfusion. Blood pressure, and
thus perfusion pressure, is only one of determinants tissue perfusion, cardiac output, regional blood
flow distribution and microcirculatory perfusion are the other key determinants of tissue perfusion.
When discussing early versus delayed norepinephrine administration, we are thus discussing the
balance between vasoconstriction preserving tissue perfusion and flow.
To which extend hypotension can be tolerated and for how long? Observational data suggest
that the more severe the hypotension, the shortest is the time that can be safely spent at this level of
pressure (4). Some observational studies also suggest that the delay between onset of hypotension and
initiation of vasopressors may be associated with increased mortality (5).
While these observational studies provide important information associating hypotension and
outcome, there is no proof of a causative association. Severity of disease may indeed be associated
with more severe hypotension and more difficulties to correct hypotension, hence a prolonged time
spent with hypotension despite efforts made to correct hypotension. At this stage, there is no proof
that rapid correction of hypotension by early initiation of vasopressors may be associated with better
outcome compared to delayed initiation of vasopressors while making important efforts to increase
organ perfusion.
Preserving tissue perfusion is often better obtained with fluid and inotrope administration than
with vasopressors. In many trials evaluating the potential effect of resuscitation strategies, optimization
of tissue perfusion was achieved using initially more fluids and more dobutamine, while vasopressor
doses were identical (6). Vasopressor also have variable effects on the microcirculation (7, 8), with
paradoxical impairment of microcirculatory perfusion at high norepinephrine doses in some patients (8).
On the other hand, fluids improve microvascular perfusion at the early stages of sepsis (9). In addition,
vasodilatory agents may sometimes improve microcirculatory perfusion in patients with septic shock
(10, 11), after adequate volume resuscitation.
In addition, vasopressor agents are associated with significant adverse effects that can also increase
the risk of death. Observational studies have shown that the higher the vasopressor load, the higher
the mortality (12). In a trial testing higher mean arterial pressure target, there was no difference in
outcome at the higher blood pressure target, but the higher pressure target was requiring higher doses
of vasopressors which resulted in a higher incidence of atrial fibrillation (13). Hence, minimizing
vasopressor doses may be a strategy in itself.
On the other hand, there are even small series of septic shock suggesting that hypotension,
sometimes severe, can be tolerated without sequalae as long as tissue perfusion is preserved (14).
Accordingly, even though observational data suggest that the severity and duration of hypotension
are associated with worse outcome, there are no data at this stage supporting the early use of
vasopressors, before optimization of tissue perfusion. As shock is characterized by an inadequate
tissue perfusion, optimizing tissue perfusion should be the first target of our resuscitation efforts, and
restauration of perfusion pressure is only one part of this strategy that should not prevail the other
efforts that are usually more efficient.
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2.3. SESION III. Personalize Sepsis Care
2.3.1. Is Sepsis So Heterogeneous?
Jean-Louis Vincent
Dept of Intensive care, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium
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Sepsis is defined as a dysregulated host response to infection, which results in organ failure.
Although patients with sepsis may often present with similar signs of sepsis, e.g., fever, tachycardia,
tachypnea, raised white blood cell count, . . . , sepsis is in fact a hugely heterogeneous condition, in terms
of the patient (age, sex, comorbid conditions, current treatments), the underlying infection (causative
microorganism, source of infection, antimicrobial susceptibilities), the degree and components of the
immune response, and the severity and numbers of organs affected. Indeed, sepsis is a syndrome,
not a single disease entity and characterizing the different aspects of sepsis heterogeneity is complex.
However, although patient, infectious and organ failure factors all increase heterogeneity and should
be taken into account when managing patients with sepsis, e.g., when considering which fluids to
give, whether or not to transfuse, etc., perhaps the most difficult aspect of heterogeneity to assess and
characterize is that related to the immune response. Indeed, the immune response varies between
patients and in the same patient during the course of their sepsis process. One of the main reasons
behind the apparent failure of anti-sepsis therapies in clinical trials is that the trials have included
poorly-characterized, heterogeneous populations of patients with sepsis, particularly in terms of their
immune status. Some of these patients will have responded to the intervention in question, but others
will not, making the overall trial result neutral or negative.
Rather than grouping all sepsis patients as the same and treating them all using one fixed
protocol or one immunomodulatory agent, patients need to be managed as individuals. Inherent
to the heterogeneity of sepsis is the understanding that there will never be a magic bullet therapy
that will be effective in all patients with sepsis. Using complex analysis of large amounts of clinical
data, studies have begun to identify patients with different sepsis phenotypes who may respond
differently to different treatments. ’Omics approaches are also enabling identification of subsets of
patients with sepsis who could benefit from different therapeutic approaches and interventions. Better
characterization of sepsis phenotypes should also enable clinical trials of sepsis interventions to enroll
more homogeneous populations of patients most likely to derive benefit. Improved understanding of
the heterogeneity of sepsis and a greater ability to characterize it will help us treat our patients more
effectively and improve patient outcomes.
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2.3.2. Rational for Probiotic Therapies as Infection Prevention Measures
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Background
ICUs serve as reservoirs of healthcare-associated pathogens that rapidly colonise the oropharynx
and intestines of critically ill patients. Broad scale use of antibiotics in ICUs further induces substantial
perturbations in patients’ microbial ecology resulting in overgrowth of opportunistic pathogens
that could cause ventilator-associated pneumonia (VAP) if aspirated, and other hospital-acquired
infections (HAIs). Studies in resource-rich ICUs have shown a beneficial effect of so-called ‘selective
decontamination’ strategies with oral and enteral application of non-absorbable antibiotics throughout
admission in the ICU, probably through the promotion of ‘colonisation resistance’ against opportunistic
healthcare-associated microorganisms. A number of randomised trials from the Netherlands
convincingly show that implementation of so-called ‘selective decontamination of the digestive
tract’ (SDD) reduces ICU mortality and VAP. In many countries, however, these strategies raise
concerns since the pre-existing digestive tract flora of patients on admission often contains multidrug
resistant microorganisms. This includes increasing levels of resistance against antibiotics used in the
above-mentioned SDD strategies, such as colistin.
Probiotics
Probiotics are live microorganisms that promote colonisation resistance when administered in
adequate quantities. Probiotic therapy has the potential to reduce the load of pathogenic bacteria, and
improve survival through prevention of HAIs and VAP. The results of one recent meta-analysis of 30
trials (2972 patients) suggest beneficial effects of probiotic therapy in ICU patients (1). Probiotic therapy
was associated with a significant reduction in HAIs (RR 0.80 [0.68–0.95], P = 0.009; I2 = 36%) and VAP
(RR 0.74 [0.61–0.90], P = 0.002; I2 = 19%). Subgroup analysis indicated that the greatest improvement
in the outcome of infections was in studies with a high mortality rate (RR 0.74 [0.57–0.96]; I2 = 58%,
P = 0.01) than in studies with a low mortality rate (RR 0.85 [0.66–1.11]; I2 = 23%, P = 0.27). Another
meta-analysis with trial sequential analysis (TSA) confirmed the finding of the abovementioned
meta-analysis that probiotics could reduce the incidence of VAP in mechanically ventilated ICU
patients (2). The TSA result showed that 1969 (62.9%) of the required information size of 3132 patients
was accrued. The cumulative z-curve crossed the conventional boundary for benefit and crossed
the trial sequential monitoring boundary for benefit, indicating that firm evidence of probiotics for
preventing VAP was obtained. One large trial of probiotic therapy in ICUs (the ‘PROSPECT’ study) is
currently running in Canada, USA and Saudi Arabia (Clinicaltrials.gov, NCT02462590). Results of
this trial are not expected before end of 2020. A large study in Indian neonates showed that probiotic
therapy prevents neonatal sepsis and death (3). A recent Japanese single centre study randomising
individual patients with sepsis admitted to ICU showed a beneficial effect of probiotic therapy on the
incidence of VAP and diarrhoea during ICU admission (4).
Conclusions
Taken together, the evidence thus far shows that probiotic therapy is a very promising intervention
to prevent infections, in particular HAIs and VAP, warranting further evaluation.
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2.3.3. CRP and Albumin Kinetics in Community-Acquired Bloodstream Infections
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The unique personal identifier given to all residents in Scandinavian countries enables merging
between administrative health registries, in which the main advantages include the reporting of
population-based results and high statistical precision due to a large number of patients. Besides, the
Danish public health system is tax financed and free of charge for all residents.
Community-acquired bloodstream infection (CA-BSI) is a well-defined infectious clinical entity
that is associated with high morbidity and mortality. We have previously reported the prognostic
prediction of one-time levels of C-reactive protein (CRP) and plasma albumin (PA) in patients with
first-time CA-BSI from a geographically well-defined Danish region. In the same cohort, we recently
found that the levels of CRP and PA were inversely correlated before, during and after the CA-BSI
episode, even after adjustment for other clinically important cofounders, such as sepsis criteria or
organ dysfunctions. With the present analysis our aim is to study CRP and PA kinetics around a
CA-BSI diagnosis.
The ideal study cohort should have the same number of biochemical specimens with equal time
intervals between these (as in well-designed prospective studies). This is recognized as a limitation of
observational studies that present different sample numbers and time intervals between the patients.
However, few, if any, studies have assessed whether this has an impact on biomarker trajectories.
We therefore evaluated the impact of the number of specimens on CRP and PA trajectories around the
diagnosis of CA-BSI. We studied data from 2418 CA-BSI patients, evaluating CRP and PA specimens
from 30 days before through 30 days after the diagnosis of CA-BSI (D0). We divided our cohort
in four subgroups based on whether specimens were occurring or not in days -30/-1, 0, 1/7 or 8/30.
We showed that the mean CRP rose on day -5 and reached its peak on day 1 and the mean PA remained
unchanged between day −30/0 and day 1 where it declined abruptly, followed by a slow increase
thereafter. Importantly, CRP and PA trajectories around the CA-BSI episode did not differ between
the four subgroups. In other words, they were independent of the number of specimens as well as
the time intervals between specimens. These findings enable us to perform longitudinal analyses of
real-life data in population-based studies.
Early changes in biomarker levels probably occur sometime before the BSI is diagnosed. It has
clinical relevance to understand when the host inflammatory response begins. So far, this issue has not
been fully addressed, particularly in community-acquired infections. Our next study was to evaluate
the kinetics of CRP and PA in the 30 days before the CA-BSI. From our population-based CA-BSI
database we identified 658 patients with at least one measurement of CRP or PA from day −30 (D−30)
through day −1 (D−1) before D0 and a measurement of the same biomarker at D0 or D1. We found
that the CRP and PA concentrations began to change inversely some days before D0, CRP increasing
by day −3.1 and PA decreasing by day −1.3. From D−30 to D−4, the CRP kinetics (expressed as slopes)
was −1.5 mg/L/day. From D−3 to D1, the CRP slope increased to 36.3 mg/L/day. For albumin, the slope
between D−30 to D−2 was 0.1 g/L/day and changed to −1.8 g/L/day between D−1 and D1. We thus
clearly showed that the biomarker levels, used as surrogates of the host inflammatory response, began
to change some days before the CA-BSI diagnosis, CRP 3.1 days and PA 1.3 days before.
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The last analysis aimed to evaluate the CRP and PA kinetics in response to antibiotic therapy as
a predictor of short- and long-term mortality (D4-D30 and D31-D365, respectively). From the same
population-based CA-BSI database we identified 935 patients with CRP and PA measurements on day
1 (D1) and D4 to evaluate the relative CRP variations in relation to the CRP value on D1 (CRP-ratio).
The patients were classified according to the CRP-ratio pattern of the response previously published as
fast response, slow response, non-response, and biphasic response. At D4, the CRP-ratio was lower
in the survivors on D365 in comparison with D4-D30 non-survivors and D30-D365 non-survivors
(p < 0.001). In comparison with patients alive on D4 with a fast response, those with non-response and
a biphasic response had a 2.74 and 5.29 increased risk of death in D4-D30, respectively, and a 2.77 and
3.16 increased risk of death in D31-D365, respectively. The PA levels remained roughly unchanged from
D1-D4, but a lower PA predicted a higher short- and long-term mortality (p < 0.001). The ability of the
CRP-ratio and D1 PA to identify patients with a poor short- and long-term mortality after adjustments
presented an acceptable discriminative performance (AUROC = 0.79). In this analysis, we showed
that serial CRP measurements after CA-BSI diagnosis are clinically useful as early as D4 to identify
patients with a poor outcome. Besides, the identification of individual patterns of CRP-ratio response
further refines our ability to prognosticate either short- or long-term mortality. The addition of the
D1 PA further increases this ability. And again, we validate the concept of the CRP-ratio pattern of
response to antibiotics, as found previously in another cohort of patients (Povoa P et al. Eur Respir J
2005;25:804–812).
In conclusion, we showed that CRP and PA kinetics around a CA-BSI diagnosis could be useful
in the early identification of patients that will develop a CA-BSI, and in addition, the assessment of
the rate of the CRP-ratio change in response to antibiotic therapy, as well as the identification of the
pattern of response, are well correlated with early and late mortality.
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2.4. SESION IV. New Therapies in Sepsis
2.4.1. Immunological Profiling in Sepsis
Jesús F. Bermejo-Martin 1,2
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The primary cause of sepsis is an infection. Infection results from the inability of the host immunity
to prevent invasion by a microbe. Sepsis is the most extreme consequence of an infection, when this
causes organ failure. While the microbial side is extensively studied during the clinical management of
sepsis patients, the immunological side is not. Interestingly, profiling host immune status and responses
during sepsis has much to offer [1]. Both in sepsis [2] and severe pneumonia [3], there have been
described a number of immunological phenotypes that are able either to predict sepsis development,
to contribute to the early diagnosis of sepsis, and to identify individuals at risk of poor prognosis.
We need to make worth these phenotypes to prevent and better treat sepsis patients. Lymphopenia
increase risk of sepsis when it is present in individuals at the community [4], but also is an indicator
of sepsis when it is established. Low expression levels of HLA-DR on monocytes identifies those
sepsis patients at risk of developing secondary infections. Low levels of endogenous immunoglobulins
in sepsis patients with moderate severity predict mortality [5]. Fail to expand neutrophil counts in
blood is a sign of poor prognosis in septic shock [6]. Patients severe influenza [7] or sepsis [8] with
transcriptomic signatures denoting adaptive immunity suppression are at higher risk of mortality.
Profiling these phenotypes in sepsis patients could help to develop predictive enrichment strategies in
order to identify those patients who potentially will respond better to immunotherapy. To this regard,
finding out if a patient present with predominant signatures of inflammation or immunosuppression
or both, will help to elucidate if he/she deserve drugs attenuating inflammation or boosting immunity,
or a combination. Finally, the role of immunocompetence status in deciding antibiotic discontinuation
has been neglected [9]. Does the antibiotics have the same opportunities to control infection in a
patient with a severe depression of his/her immunity? The emergence of point of care devices such
as Accelix TM to automatically profile HLA-DR on the surface of monocytes or Leuko TM to profile
leukocyte counts in a non invasive manner, or the Nexus IB10 TM technology to profile biomarkers at
the bedside od the patient will contribute to make reality the promise of immunological monitoring in
sepsis. Finally, combined profiling of both endothelial and immunological markers could help to early
detect the presence of organ failure during an infection [10].
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2.4.2. Cell Therapies in Sepsis: New Insights
Gonzalez H., Masterson C and Laffey J.G.
Background
Acute respiratory distress syndrome (ARDS) is a life-threating critical illness, characterised by a
severe pro-inflammatory response causing lung injury, which can progress to multiple organ failure
and death (1). ARDS is seen in 23% of mechanically ventilated patients in the ICU (2), and represents
10.4% of global ICU admissions, with small variances between continents (3). Despite the improvement
in critical care support in the last number of years, 40% of ARDS patients die in hospital. The need for
an effective and safe treatment for ARDS promotes the search of alternative approaches. Here we focus
on cell therapy, specifically mesenchymal stem cells, which have demonstrated potential for ARDS.
Pre-Clinical Studies Supporting Cell Therapy
MSCs are adult derived stem cells that can be isolated from various sources as bone marrow (BM),
adipose tissue (AD) or umbilical cord (UC). MSCs present low levels of MHC I expression and virtually
no MHC II or costimulatory molecules, allowing allogenic transplant without immune rejection (4).
MSCs have potent immunomodulatory effects; reprogramming the immune response to reduce tissue
damage and enhance their tissue repair capacity. From a logistic point of view, the multiple sources and
their capacity of stable in vitro expansion, whilst maintaining an undifferentiated state and retaining
activity, permits the escalated production of these cells for clinical use.
In preclinical ARDS models, MSCs improve survival in LPS-induced acute lung injury, decreasing
oxidative stress and inflammation (5). Devaney et al. demonstrated that MSCs reduce lung bacterial
burden and improve survival in an E. coli pneumonia model (6) and Mei et al. reported similar
effects in a systemic infection model (7). MSC’s capacity to improve damage caused by mechanical
ventilation has been reported as well, whereby Curley et al. demonstrated enhanced recovery after
MSC administration in a ventilator-induced lung injury model (8).
Med. Sci. 2020, 8, 13 21 of 54
Clinical Studies
In recent years, phase 1 clinical trials have reported on the safety of MSCs for different diseases
(9). Wilson et al. have shown in ‘The STem cells for ARDS Treatment’ phase I pilot trial (START;
NCT01775774), that intravenous administration of bone-marrow derived MSCs in nine patients with
moderate to severe ARDS did not present any safety issues (10). The same group in early 2019 presented
the results from a phase 2a safety trial (NCT02097641) where 60 patients received a single dose of
10 million BM-MSCs/kg or placebo. While there were no adverse effects reported related to the MSCs
administration, mortality was non-significantly higher in the treatment group (11). Recently, positive
safety outcomes from the phase 1/2 MultiStem® Therapy in Acute Respiratory Distress Syndrome trial
(MUST-ARDS; NCT02611609) were announced with an inference toward efficacy of high doses of MSCs
in ARDS patients [Bellingan, 2019]. Ongoing clinical studies include the ‘Repair of Acute Respiratory
Distress Syndrome by Stromal Cell Administration’ (REALIST; NCT03042143), where patients are
receiving human umbilical cord derived MSCs. MultiStem® therapy is also being investigated in a
phase 1 trial in patients with pneumonia-induced ARDS (ONE-BRIDGE; NCT03807804). In late 2019
Japan’s Ministry of Health, Labour and Welfare conferred orphan regenerative medicine designation
to MultiStem® therapy for ARDS.
Clinical trials in syndromes related to ARDS such as sepsis and septic shock have been performed.
A Russian clinical trial using mesenchymal cells in septic shock and severe neutropenia (RUMCESS,
NCT01849237) suggested an improvement in the short-term survival in septic shock patients after MSC
administration (12). Recently, the ‘Cellular immunotherapy for septic shock’ (CISS; NCT02421484)
phase 1 trial results has demonstrated the safety and tolerability of BM-MSCs up to 250 × 106 cells
in septic shock patients (13). The same research team is developing a phase 2 clinical trial (CISS2;
NCT03369275) enrolling 114 participants to confirm the previous results. There are more clinical
trials ongoing at the moment, targeting the treatment of severe infections with MSCs (CHOCMS;
NCT02883803).
Challenges and Future Opportunities
Our understanding of the biology of MSCs and their mechanisms of action in ARDS has vastly
improved in the last number of years, but many questions still remain unanswered. The translation
of this therapy to the clinic still presents some issues that have to be addressed to maximize
therapeutic potential. Differences between batches of cells, optimizing cell cryopreservation and
thawing approaches, all require further research. The administration time of the MSCs appears to be
crucial for the outcome, and most of the pre-clinical studies have focused on the early administration
of the cells, a situation not always possible in the clinic.
Despite the remaining challenges for the future, new studies are exploring different approaches to
solve the current limitations and improve MSC effcacy. Recently Jerkic et al. showed improved efficacy
using UC-MSCs over-expressing IL-10 in resolving E. coli lung infection in a pneumosepsis rodent
model (14). There is also ongoing research involving the use of MSC products instead of the cell itself,
avoiding any perceived problems with administration of cells, such as pulmonary circulation micro
emboli or infusion toxicity. Studies have demonstrated the therapeutic potential of the whole MSC
secretome, while others have shown the potential for purified MSC-derived extracellular vesicles and
exosomes in lung injury models (15, 16). Also, alternative delivery routes are under study to facilitate
their use in the clinic. Recently McCarthy et al. has shown that nebulised MSC conditioned media
retains antibacterial properties against clinically relevant pathogens (17).
Conclusions
MSCs demonstrate considerable therapeutic promise for ARDS. Increasing insights exist into
their diverse mechanisms of action, including their modulation of the immune response, ability to
reduce host injury by attenuating the pro-inflammatory response, increasing bacterial clearance, and
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facilitating repair. Encouraging safety data is emerging from phase I and phase II clinical trials.
However, better characterisation of MSCs will address current knowledge gaps, and should maximize
the therapeutic potential of MSCs for ARDS.
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2.5. SESION V: Severe Pulmonary Infections
2.5.1. Animal Models in VAP
Ana Motos Galera
Hospital Clinic de Barcelona, Barcelona, Spain
Ventilator-associated pneumonia (VAP) is a type of lower respiratory tract infection that develops
≥48 h following mechanical ventilation (1,2). VAP is the leading cause of mortality and morbidity
in critically ill patients among nosocomial infections (1, 2). VAP may be caused by a variety of
pathogens and, in many patients, more than one pathogen can be isolated (3,4). The most frequent
causative pathogens are Gram-negative bacilli, such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella
pneumoniae, or Acinetobacter baumannii, while Staphylococcus aureus is the most common Gram-positive
pathogen (5). Bacterial resistance to multiple antibiotics has become increasingly frequent in patients
with VAP by Gram-negative pathogens and existing antibiotic therapies are often ineffective. Patients
at risk of being colonized by multi-drug resistant pathogens are extremely heterogeneous, often
present several co-morbidities, and many receive antibiotics prior to and during the course of their
hospitalization (6). Additionally, the pattern of resistance varies widely among institutions and
departments (7). As a consequence, the mortality associated with VAP has not substantially decreased
over the last decades, despite improvements in treatment and intensive care support.
In the last 20 years, different animal models have allowed us to elucidate the pathogenesis of
VAP, but also to test novel therapies and equipment as well as study the pharmacology (8). Hence,
animal models have become a decisive step between in vitro testing and clinical studies. In this
scenario, a wide variety of animal models of pneumonia has been developed (8,9). Most of the
experimental studies are performed in mammals; specifically, in the last decades, studies in rodents
have gained increasing interest. These small animal models are commonly used because their size, rapid
reproductive rate, potential for extensive genome manipulation and limited costs (10). Nevertheless,
significant anatomical and physiological differences between rodents and humans have been noted
(11). In addition, long term mechanical ventilation and ICU-related concomitant conditions are
challenging. Also, the severity of the infection can quickly kill small animals, which hinders the
long-term effectiveness of novel therapies (10,12).
Therefore, several models in large animals such dogs, cats, pigs, sheep or non-human primates
have been described (13–17). Currently, dogs, cats and non-human primates have been replaced to
sheep and pigs due to the ethical requirements related to the care and use of research animals and
the public concern for these pet species. Large animal models are close to human anatomical features
admit prolonged mechanical ventilation and reproduce intensive care settings (12). However, sample
size of these studies is limited by their significant expenses, intensive labour and high time-consuming.
Furthermore, large animal models are young healthy animals without comorbidities and deeply
sedated throughout the experimental studies; a different scenario that we find in the intensive care
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units. Contrarily, these circumstances help to test different hypotheses and novel approaches without
prior medication interference or comorbidities (12).
In this context, animal models constitute the basis for the successful development of novel therapies
and innovative preventive and therapeutic approaches for VAP, although differences with respect to
the VAP in humans must be taken into account before drawing translational conclusions (18,19).
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2.5.2. Hospital-Acquired Pneumonia in Non-Ventilated Patients
Miquel Ferrer
RIICU, Department of Pneumology, Respiratory Institute, Hospital Clínic of Barcelona, IDIBAPS,
CibeRes, Universitat de Barcelona
Most studies on hospital acquired pneumonia (HAP) are focused in mechanically-ventilated
patients. The incidence of pneumonia in this population, namely ventilator-associated pneumonia
(VAP), is higher compared with non-ventilated patients. VAP has elevated morbidity and mortality,
and the responsible micro-organisms are well defined in VAP. Therefore, it is likely that there may be
bias due to extrapolation this information to non-ventilated HAP.
Few studies evaluated HAP in non-ventilated patients, mainly outside the intensive care unit
(ICU) until recently. The rate of etiologic diagnosis of pneumonia is higher in VAP. A multicentre
Spanish study reported higher proportions of “community” and environmental organisms, and lower
proportions of non-fermenting (NF) gram-negative bacilli (NF-GNB), compared with series on VAP.
However, multi-drug resistant (MDR) pathogens are sufficiently frequent in non-ventilated patients to
be considered in the empirical antibiotic treatment. In addition, the outcomes of HAP in non-ventilated
patients of these series are better compared with VAP patients.
Non-ventilated patients outside the ICU are expected to have less severe underlying clinical
condition than ICU patients. Conversely, ICU patients are expected to have more frequent risk factors
for specific pathogens. Therefore, several studies addressed the question on whether the different
aetiology and worse outcome of VAP depend on previous intubation or higher severity of the host.
It is estimated that only 30% patients admitted in ICUs are mechanically-ventilated for more than
24 h. Among published series on ICU-acquired pneumonia, the proportion of non ventilator-associated
HAP ranges between 4% and 73%. In general, patients with non-ventilator ICU-acquired pneumonia
have: (1) similar baseline severity than VAP patients, although less organ system failure; (2) older
age, possibly because the oldest patients are more likely to have previous do-not-intubate decisions;
and (3) pneumonia occurred earlier in the ICU than VAP, because they may have less protection from
aspiration while they are critically ill and because endotracheal intubation may facilitate removal of
bronchial secretions and delay infection.
As in HAP outside the ICU, there is a lower rate of etiologic diagnosis patients with non-ventilator
ICU-acquired pneumonia than in VAP patients, probably due to less availability of LRT samples
of high quality for microbiology, and less bacterial burden due to shorter previous critical illness.
The most frequent bacterial isolated are enteric GNB, NF-GNB and Staphylococcus aureus. Although
these microbes are more frequency isolated in VAP patients, there are no major differences in the types
of isolates when these rates are corrected for patients with aetiology. Community-acquired pathogens
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such as Streptococcus pneumoniae appear to be more frequent in NV-ICUAP. Therefore, aetiology may
depend on both patients’ underlying severity and previous intubation. Therefore, similar empiric
antibiotic treatment of pneumonia is advisable between ventilated and non-ventilated ICU patients.
Finally, the long-term mortality is slightly lower in patients with non-ventilator ICU-acquired
pneumonia; however, when adjusting for confounders, the mortality is similar in both types of
patients, probably because of the similar baseline severity and the limited attributable mortality of VAP.
However, patients with non-ventilator ICU-acquired pneumonia who need subsequent intubation
have a particularly higher mortality; they represent a group of patients with non response to the
empiric treatment.
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2.5.3. Hyperoxemia as a Risk Factor for Ventilator-Associated Pneumonia
Saad Nseir 1,2
1 Lille University Hospital, Critical Care Center, F-59000 Lille, France; s-nseir@chru-lille.fr
2 Lille University, U995-LIRIC-Lille Inflammation Research International Center, F-59000 Lille, France
High concentrations of oxygen are routinely used during the supportive care in critically ill
patients. Although existing data remain conflicting regarding the risk related to hyperoxemia in
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critical care, results from the latest clinical studies suggest that hyperoxemia is probably associated
with worse outcomes in some critically ill patients. Potential reasons for these conflicting results are
significant heterogeneity between the studies regarding hyperoxemia definition, time of assessment,
timing and duration of hyperoxemia. Two meta-analyses [1, 2] suggest that hyperoxemia is associated
with increased mortality in different populations of critically ill patients (8,9), including post-cardiac
arrest [OR =1.42 (1.04–1.92), I2 = 68%], stroke [OR =1.23 (1.06–1.43), I2 = 0%], and traumatic brain
injury [OR =1.41 (1.03–1.94), I2 = 65%]. In addition, a recent single-center randomized controlled trial
reported increased mortality in patients with conventional therapy, as compared with conservative
oxygen therapy [3].
Recent studies suggest a relationship between hyperoxemia and ventilator-associated pneumonia
(VAP). Hyperoxemia is responsible for denitrogenation phenomena, and inhibition of surfactant
production, promoting atelectasis in mechanically ventilated patients. Further, hyperoxemia impairs
the efficacy of alveolar macrophages to migrate, phagocyte and kill bacteria. Oxygen can also cause
pulmonary-specific toxic effect called hyperoxic acute lung injury leading to longer duration of
mechanical ventilation [4]. All these hyperoxic effects are well-known risk factors for VAP. Entezari
and colleagues [5] showed that prolonged exposure to hyperoxaemia impaired macrophage capacities
to phagocytose Pseudomonas aeruginosa. Another study found hyperoxaemia to be associated with
increased serum concentration of high mobility group box 1 (HMGB-1), and increased mortality in mice
infected with P aeruginosa. In a mice model exposed to hyperoxaemia, ascorbic acid supplementation
significantly improved bacterial clearance of P aeruginosa, and reduced accumulation of HMGB-1, and
reactive oxygen species in the lung. Our group performed a retrospective analysis of prospectively
collected data in a cohort of 503 patients receiving invasive mechanical ventilation for more than 48 h
[6]. Hyperoxaemia was identified as an independent risk factor for ventilator-associated pneumonia
(OR 1.1, 95% CI 1.04–1.2 per day, p=0.004). However, two recent randomized controlled trials evaluated
the impact of conservative oxygen strategy versus a liberal strategy, but did not confirm the role of
hyperoxemia in lower respiratory tract infection occurrence.
Further large prospective studies in carefully selected groups of patients are required to confirm
the potential role of hyperoxemia in VAP pathogenesis and to evaluate the impact of a conservative
oxygen strategy vs. a conventional strategy on the incidence of VAP.
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2.5.4. Role of Endotracheal Tube Biofilm in VAP
Laia Fernández Barat
Research laboratory coordinator, Ciberes-IDIBAPS, University of Barcelona
Among 65–80% of human infections are associated to biofilms, especially in respiratory infections
or those associated with indwelling medical devices such as endotracheal tubes (ETT) [1,2]. Biofilms
develop rapidly following endotracheal intubation, with well-organized antibiotic-tolerant microbial
structures that represent a persistent source of pathogens in the critically ill patient [3]. Whether this
colonization of the ETT is a direct cause of ventilator associated pneumonia (VAP) or a concomitant
fact associated with the spread of microorganisms from the tracheobronchial tree to the tube during
intubation is difficult to assess because ETTs can only be obtained after extubation, since re-intubation
itself represents an independent risk factor for nosocomial pneumonia [4]. However, ETT-biofilm is
considered one of the multiple pathophysiological mechanisms that lead to (VAP) and/or its relapses [5].
Animal and clinical trials have already tested biofilm-preventive measures. In particular,
the Silver-coated ETTs and the Mucus Shaver evidenced successful results in terms of biofilm
prevention [6–8]. Nevertheless, these preventive measures are associated with the increased costs, not
easy to implement and thus they are not yet universally adopted.
Recently, studies have evidenced that VAP patients have lower biodiversity in lung microbiota in
comparison to the same subjects at intubation [9]. This finding sheds light into the potential role of lung
and ETT microbiota in VAP suggesting that VAP classical pathophysiology should be re-evaluated.
New parameters should be incoporated into the VAP equation such as: the imbalance in the lung
microbiome caused by an ETT and how this imbalance is propagated within ETT-biofilm also influenced
by antimicrobials, usually present in the context of ICU patients at risk of respiratory infections.
Mature biofilms exhibit antimicrobial tolerance and harbor resistant bacteria but there is scarce
evidence on the effect of systemic, aerosolized or combined regimens of antimicrobials on ETT-biofilm
formation during mechanical ventilation. Along the last 12 years, in our research laboratory we
have studied preventive and treatment strategies for ETT-biofilms in mechanically ventilated subjects
with pneumonia due to MRSA, Pseudomonas aeruginosa or Streptococcus pneumoniae. As a result, and
through the standardizing of the methodology we have unveiled novel aspects of in vivo ETT-biofilms
development [10], as well as the effect of different preventive [11,12] and treatment strategies some of
them already applied in clinical practice13, or close to, whilst others in preclinical phases.
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2.5.5. Aspiration Pneumonia
Michael S. Niederman
Clinical Director and Associate Chief, Pulmonary and Critical Care Medicine, Weill Cornell Medical
Center, New York, NY, USA
Aspiration pneumonia can occur in patients both inside and out of the hospital, and can lead to
severe illness and respiratory failure.
The term “aspiration pneumonia” is used to refer to macroaspiration of the contents of a colonized
oropharynx or stomach. When an aspiration event occurs, it can be of bacteria, gastric acid or inert
material (eg. blood). When bacteria are aspirated, the development of pneumonia depends on the
virulence of the organisms, the size of the inoculum, and the state of the patient’s host defenses.
The identity of the etiologic organisms depends on the site of acquisition (home, hospital, etc.).
Aspiration pneumonia not only occurs in patients with appropriate risk factors (altered consciousness,
protracted vomiting, mechanical disruption of defense barriers, sedating medications, impaired
cough and swallowing or gastric problems) but occurs in characteristic anatomic locations, primarily
gravity-dependent regions of the lung such as the lower lobes or posterior upper lobe, and more on
the right side than the left. In the ICU, as many as 20% of patients have dysphagia and aspiration
post extubation and many of them continue to aspirate at the time of hospital discharge. Also in the
ICU, patients who have hypothermia therapy after cardiac arrest are especially at risk for aspiration
pneumonia, within 2–4 days post event, since hypothermia can impair host defenses, and urgent
intubation post arrest can promote the entry of oral contents into the lungs.
The bacteriology of aspiration pneumonia has changed from years past, with anaerobes
being relatively uncommon except in patients with poor dentition and impaired consciousness.
Gram-negative bacteria are more common than other organisms, in patients who develop pneumonia
in a hospital or chronic care facility. Clinically patients with aspiration events do not always have a
witnessed event, so suspicion should be high in those with risk factors. Conversely, not every witnessed
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aspiration event leads to pneumonia and if aspiration leads to symptoms, they can include airway
findings such as cough and bronchospasm, or parenchymal lung findings such as hypoxemia, dyspnea
and respiratory failure. Up to 16% of aspiration pneumonia can lead to ARDS, but the risk rises if
other ARDS risks are also present.
The diagnosis of aspiration pneumonia is made by a constellation of clinical features, risk factors
and radiographic findings. In the differential diagnosis is bacterial pneumonia, chemical pneumonitis,
foreign body obstruction with distal pneumonia, and negative pressure pulmonary edema, the latter
in patients undergoing intubation and general anesthesia. Biomarkers such as procalcitonin cannot be
relied on to distinguish chemical from bacterial pneumonitis.
An algorithm for therapy will be presented that differs for patients with community acquired or
nosocomial aspiration, because each has different colonizing bacteria. Although the use of antibiotics
is usually driven by the presence of radiographic abnormalities, some patients with severe illness after
a witnessed aspiration episode are also treated with antibiotics, because of the possibility of delayed
appearance of radiographic infiltrates. Duration of therapy is dictated by clinical response, but can be
as short as 5 days, and can be guided by serial measurements of procalcitonin.
Prevention is key for patients at risk for aspiration. Key interventions include: no food for 8 h
and no clear liquids for at least 2 h prior to elective surgery; 24 h of prophylactic antibiotics following
urgent intubation, especially in those with impaired consciousness, including those treated with
therapeutic hypothermia post cardiac arrest; swallowing evaluation after stroke and post extubation;
feeding in a semi-recumbent position post stroke; and preference for an angiotensin –converting
enzyme inhibitor to treat hypertension post stroke (since it can promote cough). For patients with
impaired consciousness in a long term care facility, oral care has uncertain benefit, and the use of oral
chlorhexidine remains controversial.
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2.6. SESION VI: Diagnostic Tools in Pulmonary Infection
2.6.1. New Diagnostic Approaches for Ventilator-Associated Pneumonia
Jean Chastre
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Abstract: Ventilator-associated pneumonia (VAP) is typically identified at the bedside by combining
three criteria: (1) clinical observations suggesting infection, e.g., the new onset of fever, purulent
sputum, leukocytosis, increased minute ventilation, arterial oxygenation decline and/or the need
for increased vasopressor infusion to maintain blood pressure; (2) new or progressive persistent
radiographic infiltrates; and (3) “positive” microbiological culture results for a potentially pathogenic
microorganism isolated from endotracheal aspirates (ETAs), bronchoalveolar lavage (BAL) fluid,
pleural fluid and/or blood.1 However, this VAP-case definition is frequently inaccurate and leaves
room for subjective interpretation.2 Since a new pulmonary infiltrate is the only criterion confirming
involvement of the intra-alveolar pulmonary spaces by the infectious process, it is considered a
prerequisite for the diagnosis of VAP. However, most of the time it is not present, with the infection
remaining confined to an already abnormal region of the lung, rendering useless all diagnostic
approached based on lung sonography and radiology, including CT scans.3 Indeed, most ICU patients,
if not all, demonstrate bi-basal pulmonary infiltrates when screen with CT scan or lung sonography
after ≥2 days of mechanical ventilation (MV).4 Thus, it is mandatory to consider the diagnosis of
VAP in patients who deteriorate clinically, and/or in whom vasopressors need to be increased in
order to maintain blood pressure, even in the absence of a clear-cut progression of radiographic
abnormalities. The presence of a pathogen at the level of the proximal airways does not suffice for
making the diagnosis of VAP, since most ventilated patients are colonized with pathogens very early
after the initiation of MV. Even deciding which threshold should be applied to define a “positive”
culture when using semi-quantitative or quantitative ETA or BAL fluid cultures can be problematic,
especially for specimens obtained after starting new antibiotics.3 Thus, the absence of undisputable
“reference standards” continues to fuel controversy about the adequacy and relevance of many
studies in this field and have led investigators to describe either other types of lower respiratory
tract infection, e.g., ventilator-associated tracheobronchitis (VAT), or even to abandon the concept
of VAP and replace it by a new construct that comprises different levels of “ventilator-associated
events”, including infection-related ventilator-associated condition (IVAC).5 These current limitations
in establishing a rapid and precise microbiologically confirmed diagnosis of VAP serve as the impetus
for developing new rapid diagnostic approaches for this important infection. Multiplex real-time
PCR, peptide nucleic acid fluorescence in-situ hybridization (PNA-FISH) and matrix-assisted laser
desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) are all very accurate
techniques that allow rapid detection of a broad array of respiratory pathogens to optimize empiric
antimicrobial treatment, including bacteria, yeast, mold, viruses, and mycobacteria.6,7 These platforms
are now marketed by different companies and can be used in many microbiological laboratories in
a routine manner. The benefits to this can be numerous, including potential for providing timely
administration of appropriate antimicrobial therapy as well as minimizing the use of broad-spectrum
antibiotics when they are not justified. They can also facilitate clinical trials for new anti-infective
agents by stratifying patients eligible for the trial at the earliest possible opportunity.8 However, it
is also important to understand the limitations of these new technologies. Although some of them,
including quantitative PCR (qPCR), allow determination of the absolute quantity of target DNA
in a sample according to a calibration curve, they cannot distinguish between live and dead cells.
Therefore, they could grossly overestimate the bacterial burden present in the specimens. As such,
they have an inherent limited capacity for differentiating colonization and tracheobronchitis from
true infection requiring immediate antimicrobial treatment, which could be highly problematic in
mechanically-ventilated patients. Secondly, although several genes coding for antimicrobial resistance
can be detected by molecular technologies, their mere presence does not automatically mean their
expression or production. The latter is true with the exception of a few specific mechanisms of
resistance provided by the above described molecular techniques (i.e., detection of methicillin-resistant
Staphylococcus aureus) and potentially the Accelerate PhenoTM System, which is the only FDA cleared
platform currently available that provides both pathogen identification and phenotypic antimicrobial
susceptibility using morphokinetic cellular analysis using advanced optics microscopy.9 Therefore,
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although typing tests based on qPCR and other molecular diagnostic methods are faster, their results
regarding the true susceptibility patterns of the causative pathogens should always be correlated
with phenotypic and biochemical tests. As such, it is usually not possible to de-escalate from
broad-spectrum antimicrobial coverage to a more narrow-spectrum regimen before a conventional
antibiogram is obtained. Thirdly, the deployment of these new molecular techniques is not easy and
should always be done in close collaboration with ICU doctors, embedded in a strong antibiotic
stewardship program in order to reduce the time to appropriate antimicrobial therapy in patients
infected with MDR pathogens, as well as avoiding broad-spectrum regimens when the infection can
be treated by a narrow-spectrum antibiotic.
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2.6.2. New Sensing Nanodevices for Early Diagnosis of Infectious at the Point-of-Care
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Infections and multidrug-resistance have become a major healthcare issue in the 21st Century
with millions of cases every year and with an increasing incidence of deaths. In Europe 5–10% of
all hospitalizations results in nosocomial infections, with the highest rates in surgical and intensive
care units (ICU) [1,2]. Diagnosis and management of infections in hospital settings is a very critical
task where fast and accurate results can translate into life, changing health outcomes for individuals.
This is especially severe in the case of nosocomial infections, and when the infections evolves in sepsis.
In particular, sepsis with a mortality rate of ~30% requires fast and accurate diagnosis as the survival
chances decreases by 7–8% for every hour that the infection remains untreated [3]. Rapid, sensitive
and quantifiable bacterial detection from patient blood is thus a clinical demand. Despite the advances
in the conventional diagnostic techniques, these are inherently time consuming and labour intensive
and antimicrobial therapy can render negative cultures, thus slowing the finding of the right treatment.
Thus, diagnostic tools with enhanced sensitivity and selectivity, able to prompt identify the type of
infection and the bacteria resistance profile could greatly help in the administration of the most suitable
treatment, improving the patient’s outcome.
We work in developing such clinical point-of-care (PoC) devices by employing novel nanophotonic
biosensor platforms as a powerful tool for rapid infection detection and for the identification of the
genetic sequences associated to the antibiotic susceptibility. We have demonstrated, at laboratory level,
that our biosensor technology is suitable for the rapid and label-free detection of spontaneous bacterial
peritonitis. The biosensor device is capable of detecting E. coli at extremely low concentrations (LOD:
4 cfu/mL) in human ascitic fluid, using a label-free direct immunoassay, with a time to result of only
25 min and without the need of any previous sample purification [4]. Moreover, we have developed an
ultrasensitive biosensor for the detection of genes associated with the multidrug-resistance found in
Gram-negative bacteria (as E. coli) without the need of any PCR amplification step [5]. We have detected
genes encoding several β-lactamase enzymes able to hydrolyze a broad spectrum of beta-lactams.
As a proof-of-concept, we detected two genes of the unamplified genomic DNA directly extracted
from bacteria commonly found in real samples of patients attended at Vall d’Hebron Hospital. All the
steps took 30 min, achieving a LOD of only 5.8 aM (~105 copies) [5]. This value represents one of
the most sensitive DNA detection without amplification or labeling steps reported up to date, and
demonstrates the excellent potential of our nanophotonic biosensor technology for the identification of
superbug genes.
Moreover, we have accomplished steps towards an autonomous and portable sensing platform
for providing a label-free methodology in the clinical practice, reducing the sample volume and the
time-to-result. This compact POC biosensor device has been employed for the detection of sepsis
biomarkers (bacteria, proteins and microRNAs) from real patient blood samples at Vall d’Hebron
Hospital. Our device operates with low sample volumes (10 µL) and is a quick (40 min) one-step
quantification method without the need of multiple expensive laboratory instruments, reagents or
skilled technicians, thereby offering a user-friendly fast and sensitive clinical PoC device. When
employed in the hospital, the biosensor device has enabled accurate categorization of sepsis patients
(infectious SIRS) from control groups (healthy individuals and non-infectious SIRS patients) without
false positives/negatives [6,7].
Our approach paves the way for modern implementable PoC diagnostics in the clinical settings
for infectious detection. The biosensor POC device could be employed by non-expert personnel at the
bed-side of patients and could has a strong impact in guiding quick medical decisions across various
clinical scenarios.
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2.7. SESION VII: Optimizing Antimicrobial Therapy and Prevention
2.7.1. Prevention of VAP: How We Made Progress. The ANTHARTIC trial
B. Francois
CHU Limoges and France
Ventilator-Associated Pneumonia remains the most important infectious complication in the ICU
resulting in prolongation of hospitalization, potentially increasing the risk of death but also being the
main driver of antibiotic consumption in critically ill patients. When considering the antimicrobial
resistance threat, reduction of antibiotic use is key and therefore prevention strategies against VAP
should be promoted. Within this field, very few approaches have shown efficacy and currently
outside the classical VAP bundles, no specific treatment is fully recommended and demonstrated.
Both chlorhexidine, SOD/SDD and probiotics have failed to truly confirm a beneficial effect. In this
field, monoclonal antibodies could represent an alternative option in VAP prevention with some
promising results against Staphylococcal VAP but are still in early clinical development. In fact, even
if not fully disruptive, the only promising strategy that have shown benefit is based on short-term
prophylactic antibiotics. Most of the what has been positively evidenced has been done in neuro or
comatose patients and mostly using cephalosporin. In general, the benefit is on VAP incidence and
ICU stay without significant reduction of mortality which remain mostly driven by the underlying
diseases. Patients treated with hypothermic Targeted Temperature Management (TTM), which is a
standard of care after out-of-hospital cardiac arrest (OHCA) with shockable rhythm are one of the most
at risk population for VAP during ICU stay, up to 60%, and therefore to be consider strongly for VAP
prevention. Nevertheless, the benefit of a preventive short-term antibiotic therapy has not yet been
shown prospectively in such a population. In most cardiac arrest studies, susceptible gram positive
cocci and Haemophilus influenzae are the more common bacteriae documented in early VAP. Therefore,
amoxicillin-clavulanic acid appears to be the most appropriate antibiotic to be used, since its spectrum
encompasses targeted bacteriae with a moderate selection pressure and acceptable cost. In contrast,
ceftriaxone or other cephalosporins which has been used in some trials has a broader spectrum with
associated greater selection pressure, but a lower activity on MSSA which need to be targeted in the
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OHCA population, at least in Europe. To hypothesize the crude reduction for our study, we have
considered the results from the three available RCT dealing with early-onset VAP and based on these
results, we have decided that a 25% crude reduction would be meaningful and achievable.
The ANTHARTIC study is a multicentre, placebo-controlled, randomized trial which have enrolled
ICU patients >18 years, mechanically ventilated after OHCA related to initial shockable rhythm and
treated with 32–34 ◦C-TTM. Patients with extracorporeal life supports, ongoing antibiotic therapy,
chronic colonization with multiresistant bacteria, allergy to beta-lactam antibiotics or with moribund
status were excluded. Either IV injection of amoxicillin-clavulanic acid (1 g/200 mg) or placebo was
administered 3 times a day for 2 days, starting less than six hours after the OHCA. Primary outcome
was early VAP (≤7 days) which was assessed by an independent adjudication committee based on
pre-defined strict clinical, radiological and microbiological criteria using widely accepted criteria
derived from 2010 FDA guidance. Health economic evaluation was performed during initial admission
and 12-month readmissions and MDR screening was done at admission and at D7.
198 patients were randomized and 194 were analysed. Patient care was well standardized across
participating sites not only sharing exactly the same healthcare system but also more specifically when
considering bundles to prevent VAP for which recommendations were given at time of site initiation.
After adjudication, 60 VAP were confirmed including 51 early VAP. Most VAP were polymicrobial
(60%) with microbiological documentation in the control group similar to that previously described in
European ICUs, with a predominance of Gram-negative bacteria susceptible to amoxicillin-clavulanic
acid. Antibiotic prophylaxis significantly decreased the development of early VAP (19 [19.2%] vs.
32 [33.7%]: p = 0.03; HR = 0.53; 95%CI: 0.31–0.92). Similar results were obtained when using the
5-day cut-off value to distinguish early from late VAP (cumulative incidence on day 5: 17.2% in the
antibiotic group vs. 30.5% in the control group; HR = 0.53; 95%CI = 0.30; 0.95; p = 0.03). No difference
in VAP incidence was evidenced when considering the targeted temperature management method and
no centre effect was noted. Overall, the risk of developing VAP was lower in patients who received
antibiotics (HR = 0.55; 95%CI = [0.33; 0.91]). Non-pulmonary secondary infectious complications
were equally distributed between both study arms. No difference in occurrence of late VAP (4% vs.
5.3%) and Day-28 mortality (41.4% vs. 37.5%) was observed, knowing that mortality were mostly
related to cardiac events or care limitations. Reduction of mean total costs reached €7193 per patient
in the antibiotic group when considering the overall 12-month follow-up period including initial
stay and readmissions. Some authors had suggested that such therapeutic strategy could alter the
microbiota and the epidemiology of secondary infections but in our limited sampling we only noted the
increased frequency of enterobacteria in patients treated with amoxicillin-clavulanic acid, however, the
implications are unclear. No argument supports a potential promotion of difficult-to-treat organisms
when using a routine two-day course of amoxicillin-clavulanic acid, which is in keeping with previous
studies. None of serious adverse event was considered to be related to study treatment by investigators.
A two-day antibiotic therapy with amoxicillin-clavulanic acid in patients receiving a 32–34 ◦C-TTM
strategy after OHCA with initial shockable rhythm is safe and significantly reduces early VAP and
hospital costs. Overall, this antibiotic approach combines lower costs and better outcome making
two-day antibiotic therapy a dominant strategy compared to usual care for the prevention of early VAP
and therefore could be recommended as standard of care in all OHCA patients receiving TTM. But,
whether the present results apply to all OHCA patients, including non-shockable rhythms or managed
with a different targeted temperature remains to determine.
References
1. Perbet, S.; Mongardon, N.; Dumas, F.; Bruel, C.; Lemiale, V.; Mourvillier, B.; Carli, P.; Varenne, O.;
Mira, J.P.; Wolff, M.; et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors
and influence on prognosis. Am. J. Respir. Crit. Care Med. 2011, 184, 1048–1054.
2. Davies, K.J.; Walters, J.H.; Kerslake, I.M.; Greenwood, R.; Thomas, M.J. Early antibiotics improve
survival following out-of hospital cardiac arrest. Resusc. 2013, 84, 616–619.
Med. Sci. 2020, 8, 13 36 of 54
3. Gagnon, D.J.; Nielsen, N.; Fraser, G.L.; Riker, R.R.; Dziodzio, J.; Sunde, K.; Hovdenes, J.;
Stammet, P.; Friberg, H.; Rubertsson, S.; et al. Prophylactic antibiotics are associated with a
lower incidence of pneumonia in cardiac arrest survivors treated with targeted temperature
management. Resusc. 2015, 92, 154–159.
4. Nair, G.B.; Niederman, M.S. Ventilator-associated pneumonia: present understanding and
ongoing debates. Intensive Care Med. 2015, 41, 34–48.
5. Ribaric, S.F.; Turel, M.; Knafelj, R.; Gorjup, V.; Stanic, R.; Gradisek, P.; Cerovic, O.; Mirkovic, T.;
Noc, M. Prophylactic versus clinically-driven antibiotics in comatose survivors of out-of-hospital
cardiac arrest—A randomized pilot study. Resusc. 2017, 111, 103–109.
2.7.2. New Antibiotics for Severe CAP: Ceftaroline
Antoni Torres
Pulmonology Department, Clinic Hospital, University of Barcelona, Barcelona, CIBER Enfermedades
Respiratorias, Spain
Ceftaroline is a fifth G Cephalosporin with a good activity against Gram positives including S.
pneumoniae and S.aureus MSSA and MRSA. In addition, it has a good activity against Enterobacteriaceae
non-ESBL. The registrational trials (1,2) comparing 600 mg/12 h IV with 1 g of ceftriaxone in hospitalized
CAP demonstrated significant superiority in clinical cure in favor of ceftaroline (3), when pooling
together the registrational trial results. In a subsequent randomized study (Asia CAP) using 2 g of
ceftriaxone +/− macrolide showed significant higher clinical cure rates of ceftaroline. A real world
observational study (4 Capture) showed high rates of clinical cure of patients with CAP with the
following characteristics: elderly, patients with comorbidities, patients with renal efailure, S.pneumoniae,
S.aureus MSSA, and MRSA. According to published RCT, the recent ATS/IDSA CAP guidelines (5),
recommended ceftaroline as one of the antibiotics to be added to macrolides in the empirical treatment
hospitalized CAP.
Severe CAP in patients admitted to the ICU has a high mortality that ranges from 25% to
40% depending on the existence of shock and /or the need for mechanical ventilation (5) (despite
initial adequate antibiotic treatment). Any antibiotic that could increase the rates of clinical cure,
and eventually mortality, needs to be included in the empirical treatment of SCAP. In one bi-center
observational study in SCAP patients (6) we observed a high clinical cure rate. In addition, mortality
was significantly associated with the late administration of ceftaroline. In another study (7) using
a network meta-analysis, ceftaroline was one of the two antibiotics associated with lower mortality
in hospitalized CAP. Although there are not RCT´‘s in SCAP comparing ceftaroline to ceftriaxone or
cefotaxime, the higher rates of clinical cure, its broad antimicrobial activity including S.pneumoniae
and S.aureus MSSA and MRSA, suggests that ceftaroline should be a first -line antibiotic for SCAP.
In patients with MRSA suspicion or with influenza that have a high change to be co-infected with
S.aureus, ceftaroline is a very good choice as well.
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2.7.3. Intensive Care Units Are Epicentres for Antimicrobial Resistance Development
Jean Carlet 1 and Jan De Waele 2
1 World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France
2 University Hospital of Ghent, Ghent, Belgium
Antimicrobial resistance (AMR) is increasing rapidly to a dangerous level worldwide, both in
animals and humans. Obviously, we have not been able to protect antibiotics, this precious resource.
The environment, both inside and outside the hospitals, is also heavily involved. Effluents coming
from the hospitals are heavily colonized with high inoculum of multi-drug resistant micro-organisms
(MDRO) and contain high concentrations of antibiotics. Although most of the antibiotics are consumed
in the community, the hospitals are a very important in the emergence of antibiotic resistance, both
because antibiotics are often over-used, and because MDRO are easily transmitted from patient to
patient, via the hands of the health care professionals and equipment used. Intensive care units (ICUs)
particularly should be deeply concerned by the issue of AMR.
For many reasons, ICUs are the «epicentres» for the selection and diffusion of MDRO, and as such
they have an important role in the emergence of AMR, and therefore also in the prevention thereof.
Large scale prevalence studies have shown that up to 70% of ICU patients are treated with antibiotics on
a randomly chosen day. Antibiotics used are very often broad-spectrum drugs inducing the likelihood
that AMR may develop. The intestinal microbiome including the oropharynx, but mostly the distal gut
plays a key role in the «hidden» selection of highly resistant micro-organisms. The very high intensity
of care in the ICUs dramatically increases the risk of patient to patient cross-transmission of those
bacteria via the hand of the health care professionals, and the environment. This problem is the same
in the step-down units, in which the nurse to bed ratio is far lower. Severe infections can occur due
to those MDRO, including urinary tract infections, central line infections and ventilator-associated
pneumonia. Prolonged, and sometimes repeated antibiotic exposure selects micro-organisms which
are increasingly resistant, particularly in the gut and in the ventilated lungs. In some cases, and some
countries, severe infections with bacteria resistant to every available antibiotic have been reported.
Resistant bacteria can easily spread to the other wards of the hospital, to long-term facilities or to
the community when the patients are discharged from the ICU, in particular if the colonization of the
patient with resistant bacteria is not properly notified to the new caretaker, the general practitioner or
outpatient nursing team.
For all the above reasons, the ICU physicians and nurses have a very special responsibility in the
management of antibiotics and the prevention of development and spread of AMR.
It is very clear that AMR is consistently increasing in the ICUs worldwide. There are huge
differences between countries, regions, hospitals or even ICUs within the same facility. In a
multicentre European study on 37 ICUs, the prevalence of MRSA ranged from 0% up to 100%.
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Similar differences were noted in this study for ESBL-producing enterobacteriaceae, Pseudomonas
aeruginosa and Acinetobacter baumanii. Northern-European countries like Scandinavian ones, Iceland, the
Netherlands, Switzerland, and to a lesser extend Germany historically have low antibiotic consumption
and AMR levels. In other countries, like Italy, Greece, India, Asian countries such as China, North
Africa and Middle East countries, the level of resistance is very high, with a prevalence of ESBL or
carbapenemases above 50%. Those differences are probably mostly due to an over-consumption of
antibiotics, particularly broad-spectrum ones, and to poor hygiene practices. However, other unknown
factors may play a role.
Gram-negative bacteria resistant to almost every antibiotic are noted more and more frequently in
some ICUs, up to as much as a few percent of all pathogens in a Greek study. The development of
resistance in Escherichia coli to colistin via mcr-1 gene has been an important step in the emergence of
those truly omni-resistant bacteria.
There are many ways to limit AMR in the hospitals, in particular in the ICUs and step-down units.
The two main actions are antibiotic stewardship, in order to decrease antibiotic consumption and
improve antibiotic management, and infection control programs, in order to limit cross-transmission of
pathogens. Other actions can be discussed, most of them targeting the digestive microbiome, such as
selective digestive decontamination (SDD) with non-absorbable antibiotics for all ventilated patients
or just to treat an outbreak due to MDRO, probiotics, bacteriocins, bacteriophages or faecal microbiota
transplantation (FMT). Data are still rather scarce to define the efficiency of those recent methods.
Those methods to control AMR will be describe in the talk.
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2.8. Poster Presentations
2.8.1. Pneumonia in ICU for Enterobacteria Ceae: Comparative Analysis between Resistant and
Multisensible Bacterial
Daniel Franco Molano, Mario Villabón, Mario Gómez, Edgar Beltrán, Alejandra Cifuentes,
Ivan Robayo, Diana Rodríguez and Sergio Ordoñez
Intensive care Department, Fundation University of sciencies of Health, Hospital San Jose.
Bogota-Colombia
Introduction
Pneumonia is the first cause of infectious etiology with an indication of admission to the ICU.
It is associated with high rates of morbidity and mortality. In low proportion, gram-negative
bacteria are the cause of such infections, however, an increase has been progressively seen, especially
by multidrug-resistant enterobacteriaceae. In this study we describe the causes associated with the
infection and prognosis, in patients with gram-negative multiresistant and multisensitive gram-negative
enterobacteriaceae, with admission to the intensive care unit.
Methods
Retrospective observational analytic study of patients diagnosed with severe pneumonia and
admission to the mixed intensive care unit of the San José Hospital in Bogotá—Colombia, for 3 years
(2016–2018).
Results
During the analyzed period, a total of 53 patients were treated for pneumonia with isolated
gram-negative bacilli, with community-acquired pneumonia 18.8%, health-associated pneumonia
13.2% and nosocomial pneumonia 68%. 33 patients had a diagnosis of severe pneumonia due to
multidrug-resistant gram negative (MDR) and 20 patients due to multisensitive gram negative (MS).
The average age of MDR infection was 66.1 years vs. 59.1 for MS, with an APACHE II of 18.7 for MDR
and 15.4 for MS. 65% of patients infected with MDR germs had multiorgan dysfunction. Within the
background, 33% of the patients had chronic lung disease without statistical differences between the
presence of antimicrobial resistance in the etiology. 100% of patients required invasive mechanical
ventilatory support upon admission. Regarding the prognosis, a statistically significant difference was
observed for MDR infections, which had longer days of mechanical ventilation 12.6 SD 8.8 vs. MS
infections 8.7 SD 5.2. Regarding days of stay in the ICU, MDR infections had 18.1 SD 10 vs. MS infections
15.3 SD 9.3 and in mortality 42.4% for MDR infections vs. 25% for MS enterobacteria. Klebsiella
pneumoniae was the most frequent microorganism in the two groups, with a global percentage of 37.3%,
followed by Escherichia coli 22.6% and Enterobacter with 19.1%, without statistical differences between
the two groups. 67% of the isolates had a profile of resistance to extended spectrum beta-lactamases
(ESBL) and 21 with a KPC type carbapenemase resistant pattern.
Conclusions
Patients with pneumonia severe with an indication of admission to the ICU for invasive mechanical
ventilation support, have a higher severity score and progression to multi-organ dysfunction, as well
as a greater number of days of ventilation, days of hospitalization and mortality if the infection is
due to multidrug-resistant enterobacteria compared to multisensitive germs. This difference occurs in
infections by Klebsiella pneumonia, E. coli and Enterobacter mainly.
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AGE-YEARS (SD) 63.9 (18.7) 59.1 (23.6) 66.9 (14.7) 0.01281
GENDER-M (%) 66(%) 60(%) 72(%) 0.36812
APACHE II (SD) 17.05 (6.23) 15.4(7.65) 18.7(6.54) 0.1173
MULTIPLE ORGANIC
DYSFUNCTION SYNDROME (%)
54.7 33.3 65.7 0.02202
BACKGROUND
COPD (%) 33 30 36.3 0.63836
IMMUNOSUPPRESSION (%) 12 15 9 0.50286
MECHANICAL VENTILATION DAYS
(SD)
10.6 (7.12) 8.7 (5.2) 12.6 (8.8) 0.04781
DAY STAY ICU(SD) 16.6 (12.1) 15.3 (9.3) 18.1(10) 0.3154
MORTALITY (%) 35.8 25 42.4 0.20054
PREVIOUS ANTIBIOTIC USE (%) 36 26 43 0.2113
BETALACTAMS (%) 55 80 30 0.00042
CARBAPENEM (%) 9.5 10 9 0.90448
ETIOLOGY (%)
Pseudomonas aeruginosa 7.2 5 9 0.5892
Klebsiella Pneumoniae 37.3 35.3 39.3 0.77182
E coli 22.6 30.1 15.1 0.1902
Enterobacter spp 19.1 20.2 18.1 0.8493
Acinetobacter Baumanni 2.6 5 0 0.1936
Proteus spp. 11.1 10.2 12.1 0.83366
Serratia spp. 5.1 0 10.2 0.13888
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2.8.2. HSV type 1 Multifocal Infection—Liver Failure and Brain Disfunction in Transplant Setting
Joana Ferrão 1,*, Tiago Duarte 2, Filipe Damião 3, Tânia Sequeira 2, Filipe Cardoso 2 and
Nuno Germano 2
1 Centro Hospitalar Universitário Lisboa Central, Serviço de Medicina 2.3
2 Centro Hospitalar Universitário Lisboa Central, Unidade de Cuidados Intensivos Polivalente 7
3 Centro Hospitalar Lisboa Norte, Serviço de Gastrenterologia
* Correspondence: joanabrancoferrao@gmail.com
Herpes simplex virus (HSV) infections are very common affecting up to 80% of adults during their
lifetime with a wide range of clinical manifestations. Most infections are asymptomatic or cause a wide
variety of illnesses, most commonly mucocutaneous infections. HVS infection is an uncommon cause of
hepatitis and acute liver failure (ALF). The majority of the cases are reported in immunocompromised
patients and pregnant women. In immunocompetent patients HVS hepatitis is a particularly rare
condition, with few reported cases, and progression to ALF in 74% of the cases with a mortality rate up
to 90%.
We present the case of a 34-year-old male, without prior medical history, presented to the
emergency room with fever, abdominal pain and diarrhea for three days. Fever with a maximum
peak of 40 ◦C and abdominal generalized pain, moderate intensity, without relieving or exacerbating
factors were the first symptoms. On a first approach with altered liver function tests (AST 1872 U/L,
ALT 954 U/L) with mild hyperbilirubinemia (2 mg/dL), leucopenia (3540 cells/uL), decreased platelet
count (107,000 cells/uL), CRP 200 mg/L, creatinine 1.5 mg/dL, hyponatremia 121 mmol/L, LDH and
clinical signs of dehydration, he was started on IV fluids and empiric antibiotics while the etiologic
study was ongoing. Despite adequate medical approach the patient progresses poorly with an episode
of generalized tonic clonic seizure on post ictal period, despite no apparent focal neurological deficits,
the patient remained with GCS score <8 with the need for orotracheal intubation and transfer to the
intensive care unit.
Further exams were pursued namely a lumbar puncture, with isolation of HSV DNA through PCR
reaction and also confirmatory serum HSV DNA. Despite adequate antiviral therapy with acyclovir,
clinical and analitical worsening occurred meeting criteria for ALF with a SOFA score over 15.
Optic nerve sheath diameter (ONSD) on ultrasound evaluation was <5 mm, thus indicating low
risk of intracranial hypertension. However, progressive shock with multiple organ failure persisted,
with no response to organ-specific supportive care measures. Moreover, after sedation interruption,
the patient maintained a GCS of 3 with minor pupillary reflex, no corneal or deep tracheal reflexes and
bispectral monitoring of 10.
Severe brain dysfunction, presumably associated with HSV infection more than with ALF was
considered to be a contra-indication for orthotopic liver with severe brain dysfunction, presumably
associated with HSV infection more than with ALF was considered to be a contra-indication for
orthotopic liver transplantation (OLT) (the patient was unstable to go for brain MRI). The patient died
on the 10th day of hospitalization.
This case illustrates the challenge of managing such patients: How should we face OLT indication,
in the presence of a neurological condition with such a poor prognosis? Highvolume plasma exchange
can play a role on increasing liver transplant-free survival, but no studies were published regarding
specifically ALF with severe encephalitis.(15) Based on the high mortality rates in untreated patients
and frequently delayed diagnosis, a high index of suspicion is needed and early diagnosis should
be promoted between clinicians; which raises the question: should we start thinking of routinely
performing lumbar puncture in patients with ALF, coma and clonus?
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2.8.3. Bloody Stenotrophomonas Maltophilia: A Case Series
Justina Kaklauskaitė 1, Šarūnas Judickas 2,3 and Jūratė Šipylaitė 2,3
1 Faculty of Medicine, Vilnius University. Vilnius, Lithuania
2 Institute of Clinical Medicine, Faculty of Medicine, Vilnius University. Vilnius, Lithuania
3 Vilnius University Hospital Santaros Klinikos, Centre of Anaesthesiology, Intensive Care and Pain
Management. Vilnius, Lithuania
Introduction
Stenotrophomonas maltophilia (SM) is commonly a non-virulent, but an important Gram-negative
nosocomial pathogen, which can cause various complications. The most vulnerable group is
immunocompromised patients, specifically with haematological malignancy and neutropenia,
prolonged hospitalization, pneumonia and prior treatment with broad-spectrum antibiotics.
SM infection is associated with high morbidity and mortality.
Objectives
To analyze three cases of S. maltophilia caused hemorrhagic pneumonia.
Case Reports
Case #1:
A 25-year-old male was diagnosed with acute myeloid leukemia (AML). The patient was treated
using two different chemotherapy protocols. Chemotherapy was complicated by febrile neutropenia.
The patient received broad spectrum antibiotic therapy. On the 36th day of hospitalization patient
developed acute respiratory failure, followed by active pulmonary bleeding. He was admitted to an
intensive care unit (ICU). The patient’s status was deteriorating; he was intubated. Diffuse bleeding
from both lungs was observed during bronchoscopy. Multiple organ dysfunction progressed and after
an unsuccessful cardiopulmonary resuscitation (CPR), the patient died. A day prior the pulmonary
bleeding taken blood culture revealed Gram-negative rods that were later identified as multi-drug
resistant SM.
Case #2:
A 61-year-old man was diagnosed with acute myeloid leukemia (AML). Chemotherapy did not
reach remission. Complete blood count (CBC) showed absolute neutropenia. The patient received
broad spectrum antibiotics. On the 45th day of hospitalization, the patient was presented with
orthopnea, acute respiratory failure and saturation of 65%, malaise. The patient has caught up bloody
sputum a few times and was admitted to the ICU. Respiratory failure progressed and he was intubated.
Within a few hours he developed major pulmonary bleeding. A bronchoscopy was performed and
bleeding from bronchi of right middle and lower lobes was visible, a balloon obturation of the right
intermediate bronchus was performed before an embolization of bronchial artery for right middle and
lower lobes. The bleeding continued, refractory shock progressed and after an unsuccessful CPR, the
patient died.
Case #3
A 75-year-old man with a history of acute myeloid leukemia (AML) diagnosed two months ago.
He received chemotherapy, but no remission was achieved. The patient presented with fever (up to
38.5 ◦C) and pneumonia. Sputum culture reveled methicillin resistant Staphylococcus haemolyticus.
CBC revealed neutropenia. Respiratory dysfunction evolved, he was transferred to the ICU and was
intubated. Bronchoscopy was performed. Post-contact mucosal bleeding of trachea and bronchi, blood
in bronchoalveolar lavage was observed. Bronchoalveolar aspirate was positive for multidrug-resistant
Pseudomonas spp. and SM. The patient was treated with TXM-SMX. Nevertheless, septic shock,
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pulmonary hemorrhage and multiple organ dysfunction progressed. After an unsuccessful CPR, the
patient died.Med. Sci. 2020, 8, 13 41 of 52 
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Background
Staphylococcus aureus is among the most frequently isolated microorganism responsible for
ICU-acquired pneumonia of which 29% are resistant to methicillin (MRSA). Our aim was to determine
the antimicrobial susceptibility, the associated molecular mechanisms of resistance and the epidemiology
relatedness of S. aureus strains from the endotracheal tubes (ETT) of intubated critically ill patients
with S.aureus intensive care unit (ICU) acquired pneumonia.
Materials and Methods
Clinical S. aureus (17 MRSA and 3 methicillin susceptible S. aureus) were collected from ETTs
after extubation during a prospective observational study carried out in four European tertiary
hospitals. Antimicrobial susceptibility test, using the Kirby-Bauer method was performed to
vancomycin, linezolid, ciprofloxacin, clindamycin, erythromycin, chloramphenicol, fusidic acid,
gentamicin, quinupristin-dalfopristin, rifampicin, Sulfamethoxazole/trimethoprim, and tetracycline.
Interpretation of results was carried out according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST). Molecular characterization of each resistance mechanism was
screened by PCR, electrophoresis and sequencing. Molecular epidemiology was analyzed by Multi
locus sequence typing. Phylogenetic analysis was carried out using comparative eBURST V3 software
(http://www.phyloviz.net/goeburst)
Results
S. aureus isolates were resistant to ciprofloxacin (85%), erythromycin (65%), gentamicin (35%),
tetracycline (30%), clindamycin (20%), and fusidic acid (5%). Three strains showed hetero-resistant
subpopulations to linezolid. The most frequent mutations in ciprofloxacin resistant S. aureus strains
were S84L in the gyrA gene, V511A in the gyrB gene, S144P in the grlA gene, and K401R/E in the grlB
gene. Strains resistant to erythromycin carried the ermC, ermA, and msrA genes; the same ermC and
ermA genes were detected in strains resistant to clindamycin. The aac(6’)-aph(2”) gene was related to
gentamicin resistance, whereas resistance to tetracycline was related to tetK (efflux pump). The fusB
gene was detected in the strain resistant to fusidic acid. The most frequent sequence types were ST22,
ST8, and ST217. These were distributed in four clonal complexes (CC5, CC22, CC45, and CC59).
Conclusions
High levels of resistance to second-line antimicrobials threatens the treatment of ICU-acquired
pneumonia due to methicillin-resistant S. aureus, with decreased susceptibility to linezolid and
vancomycin. The wide genotypic diversity found, even within the same ICU, reinforces the crucial
role of ICU prevention bundles in cross-transmission.
2.8.5. Carbapenem-Resistant Enterobacteriaceae Infection in Subgaleal Space Treated with
Meropenem-Vaborbactam: A Case Report
Seohyun (Claudia) Choi 1,2
1 Ernest Mario School of Pharmacy, Rutgers, The State University of New jersey, USA
2 Saint Barnabas Medical Center, Livingston, New Jersey, USA
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) is an emerging medical challenge worldwide,
mainly due to the limitation in numbers of antibiotics that are active against these organisms. Among
the different groups of carbapenemase, Klebsiella pneumoniae carbapenemase (KPC) is considered
to be the most common, but there are others reported as well [1,2]. Current treatment options for
CRE infections include polymyxins, tigecycline, fosfomycin, aminoglycosides, ceftazidime-avibactam,
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meropenem-vaborbactam, or combinations of multiple drugs [3,4]. Even with the available antibiotic
options, patients presenting with CRE infections still remain at high risk for mortality [1,5].
Meropenem-vaborbactam is a combination product of carbapenem and beta-lactamase
inhibitor with Food and Drug Administration (FDA) indication for complicated urinary tract
infections including pyelonephritis [6,7]. It showed 99% in vitro activity against Klebsiella
pneumoniae carbapenemase-producing Enterobacteriaceae. Similar to other beta-lactam antibiotics,
meropenem-vaborbactam exhibits time-dependent bactericidal activities, and renal excretion is the
major pathway of drug clearance [6,7].
CRE infections can be associated with various anatomical sites. Common sites of infection
reported from our institution are respiratory and urinary tracts. In 2011, there was an outbreak
of carbapenemase-producing Klebsiella pneumoniae from neurosurgical site infections in China [8].
However, CRE infection associated with central nervous system (CNS) is extremely rare in the
United States.
Patient Case
Patient was a 69-year-old male with subdural hematoma status post burr hole and craniotomy for
re-accumulation. After 2 months, he presented to the hospital with worsening mental status, and CT scan
of the head showed sunken craniotomy defect with midline shift, and he underwent for cranioplasty for
the defect, which was complicated by uncal herniation. During the post-operative care in the intensive
care unit (ICU), patient developed subgaleal fluid collection, which was aspirated. Both subgaleal fluid
and blood cultures showed the growth of carbapenem-resistant Klebsiella pneumoniae. The cranioplasty
implant was removed, and washout and debridement were performed. Patient’s hemodynamic status
was stable, not requiring vasopressor support. However, he was minimally responsive throughout
the ICU stay. Systemic antibiotic treatment was initiated with ceftazidime-avibactam, which was
subsequently switched to meropenem-vaborbactam according to the minimum inhibitory concentration
(MIC) result, which were 2 and 0.064, respectively. Due to the inability to administer local antibiotics,
patient was managed only with systemic meropenem-vaborbactam 2 g every 12 h intravenously, each
dose infused over 3 h. Of note, patient is end-stage renal disease receiving intermittent hemodialysis.
Repeat blood cultures remained negative 3 days after the initiation of treatment. Culture from dura
showed heavy growth initially, but repeated culture on day-10 of treatment showed scant growth of
the organisms.
Discussion
CRE infections are complicated medical condition that require multidisciplinary health care teams’
collaborative management. However, it becomes even more challenging when the site of infection
involves CNS. First of all, there are not many antibiotics that providers can utilize. In addition,
pharmacokinetic profiles of those drugs, especially newer ones, do not have reliable data for CNS
penetration or achievable concentration for optimal antibiotic activities [9,10]. Meropenem has known
distribution to cerebrospinal fluid, but the tissue distribution data for meropenem-vaborbactam or
vaborbactam alone has not been well established [10]. Due to this limitation, health care providers are
often forced to seek for primary literature to extrapolate the result to their patient cases.
Conclusions
Systemic administration of meropenem-vaborbactam showed the reduction of carbapenemase-
resistant Klebsiella pneumoniae burden in subgaleal space. Our patient case may provide a clinical data
for meropenem-vaborbactam utilization in such condition.
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2.8.6. Aspergillosis in an Immunocompetent Patient
T. Isidoro Duarte, T. Sequeira and N. Germano
Intensive Care Medicine Department, Curry Cabral Hospital, Central Lisbon University Hospital
Center, Lisbon, Portugal
Aspergillosis is a disease caused by environmental molds Aspergillus spp. Saprophytic
colonization can occur manifesting as pulmonary aspergillomas within a preexisting lung cavity, in
most cases due to tuberculosis sequelae. Tissue invasion presenting as invasive pulmonary aspergillosis
or disseminated infection afflicts immunocompromised and critically ill hosts.
We present a forty-three year old male, natural from Guiné-Bissau. Past history of type 1
diabetes mellitus and pulmonary tuberculosis 3 years ago treated with 6-month anti bacilar therapy.
He presented abdominal pain and weight loss (~30 kg) during the last year. On examination, he had
fever and a painful abdomen to palpation with no defense or signs of peritoneal irritation. Blood tests
showed leukopenia, CPR 17.8 mg/dL, LDH 185 U/L, normal kidney and liver function. Chest X-ray
showed an hypotransparency in the left pulmonary apex. Negative sputum samples for acidalcohol
bacilli. Negative HIV and viral hepatitis serologies.
During the subsequent days he maintained the abdominal pain despite therapy with
proton-pump-inhibitors and symptomatic analgesia. Upper-endoscopy showed an extensively
ulcerated esophagus and stomach with mucosa edema—negative histology for Helicobacter pylori;
positive biopsy for Aspergillus flavus. Normal abdomen ultrasound.
Because of gastrointestinal intolerance, he started amikacin, levofloxacin and rifampicin.
Associated study with computed tomography revealed pulmonary cavitated lesions filled by soft
tissue components, bilateral mycetomas and pneumatoceles; mucosal thickening of the ileus, appendix
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and right colon, without signs of ischemia or acute appendicitis. Bronchoscopy was performed and
galactomannan antigen was positive. Bronchoalveolar culture was positive for Aspergillus flavus.
Pulmonary invasive aspergillosis with diagnosed and amphotericin B were added. Echocardiogram
excluded vegetations. Evolution to shock with multiorgan dysfunction and death on the 11th day after
hospital admission.
Diabetes mellitus and active tuberculosis may cause a down-modulation in immune response,
facilitating the development of fungal infections. Invasive Aspergillosis is associated with high
mortality rates beside therapy with standard amphotericin B. New approaches and new therapies are
needed to improve patients’ outcome.
2.8.7. Combined Extracorporeal Blood Purification in Neurosurgical Patients: A Case Series
Burov A. I., Savin I. A., Abramov Т. A., Korotkov D. S. and Kostritsa N. S.
Federal State Autonomous Institution «N. N. Burdenko National Medical Research Center of
Neurosurgery» of the Ministry of Health of The Russian Federation
Introduction
Sepsis and septic shock in patients with primary brain damage of different origin can lead to or
aggravate the existing cerebral and focal neurologic symptoms due to cytokine storm, impairing the
hematoencephalic barrier.
The development of septic shock in the setting of low cerebral perfusion pressure aggravates the
cerebral damage, which may become irreversible, leading to negative outcome or death.
In clinical situations described above the blood purification may represent a valid therapeutic
option, as it aims at elimination of substances, such as cytokines, lipopolysaccharides and other
Pathogen Associated Molecular Patterns from the systemic blood flow.
In neurosurgical patients with septic shock it is feasible to use a combined approach, consisting
of cytokine adsorption and continuous renal replacement therapy (CRRT) with increased adsorption
capacity membranes.
Of note, the combination of these methods has the potential to eliminate a wider spectrum of
various substances from the blood flow in the short time.
In this study we present a case series, describing septic shock patients after neurosurgical
interventions, treated with a combined blood purification therapy, including CRRT and
cytokine adsorption.
Objective
The objective of the present study is to evaluate the effectiveness of the combined extracorporeal
blood purification in neurosurgical patients with septic shock.
Materials and Methods
5 patients with septic shock were treated with the described treatment. All the patients received
standard therapy according to the Surviving Sepsis Campaign guidelines. In 2 patients the combined
blood purification was started within 10 h after septic shock diagnosis and antibiotic treatment initiation,
the other 2 patients had the same treatment started within 20 h, and 1 patient—a day after the diagnosis
and isolated CRRT initiation. The duration of the combined blood purification was 24 h.
The procedure was performed with the Prismaflex CRRT machine in the continuous venovenous
hemodiafiltration mode. The systemic anticoagulation with heparin was performed in 2 patients, the
other 3 patients received regional citrate anticoagulation.
In 4 patients the AN69ST increased capacity dialysis membrane was used, 1 patient had a set with
lipopolysaccharide elimination capability (Oxiris). All patients had cytokines adsorber (CytoSorb)
installed into the circuit after the dialysis filter.
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In this case series, we traced the combined blood purification procedure influence on the
hemodynamics, vasopressor requirement and organ dysfunction (by SOFA score).
Results
In the course of the combined blood purification treatment 3 patients had substantial clinical
improvements. In 24 h after combined blood purification initiation their SOFA score was reduced for 8,
3, 4; in 48 h—for 7, 2, 6; in 72 h—for 8, 2, 4 respectively.
2 patients had a transient clinical improvement: their SOFA score was reduced for 1 and 2 points
in 24 h after the blood purification initiation, then for 1 in both patients at 48 h and increased by 2
points in first patient patients and decreased in 2 points in second patient in 72 h compared to start
point. In both 2 patients further deterioration was according to herniation.
In 2 out of the 3 improving patients the norepinephrine demand was reduced from 0.7 and 1 to
0.00 and 0.09 µg/kg/min within 24 h from combined blood purification start; the vasopressor demand
scarcely was changed in the patient in whom it was initially low (increased from 0.18 to 0.23) µg/kg/min.
In the 2 patients with transient improvement the vasopressor requirement was reduced within
48 h from the procedure initiation (from 2.13 to 1.8 and from 0.71 to 0.15 µg/kg/min), though due to
cerebral herniation the norepinephrine dose was later increased to more than 2 µg/kg/min.
The 3 improving patients were stabilized with the intensive care, including the combined blood
purification. They no longer required vasopressor support, their multiorgan failure regressed. In 25
days 1 patient died of intracerebral bleeding, 2 patients were transferred to rehabilitation stable.
Patients with transient clinical improvement died in 72 and 74 h after combined blood purification
start due to cerebral herniation in the setting of malignant diffuse edema.
Conclusions
In the described case series, combined blood purification used on top of standard intensive
septic shock treatment contributed to overall clinical improvement. Among the key changes were the
significant vasopressor reduction and MOF regress. The use of combined blood purification in septic
shock patients can be rational and effective, as it contributes to shock reversal. Further studies on the
method efficacy and safety in neurosurgical patients with septic shock are required.
2.8.8. The Use of Aerosolised Therapeutics in the Treatment of Ventilator Associated Infections
Elena Fernández Fernández, Marc Mac Giolla Eain, Gavin Bennett, Mary Joyce and
Ronan MacLoughlin
Aerogen, IDA Business Park, Dangan, Galway, Ireland.
Introduction
Invasive ventilation is a mainstay in the treatment of severe pulmonary infections. However,
a common caveat of this type of treatment is a ventilator associated respiratory infection, such as
pneumonia or tracheobronchitis. The administration of aerosolised therapeutics is the most effective
means of treating ventilator associated respiratory infections in mechanically ventilated patients.
Objectives
The objectives of this study are to assess the aerosolised characteristics of a selection of the most
commonly used compounds in the treatment of ventilator associated infections and examine the effect
of ventilator circuit configuration on therapeutics delivery. Two common ventilator configurations
were used, one with an active humidifier and one with a heat and moisture exchanger (HME).
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Methods
Aerosol droplet size distributions, specifically the volume mean diameter (VMD) and fine particle
fraction (FPF), were measured using laser diffraction (Spraytec, Malvern, UK). The therapeutics
analysed were Albuterol sulfate (Sigma Aldrich, Ireland), Promixin (Xellia Pharmaceuticals ApS,
Denmark), Tobramycin (Hospira UK Ltd., UK) and Amikacin (Lab. It. Biochim. Farm.Co., Spain).
Albuterol was used as a representative tracer in line with international nebuliser test standards,
ISO27427. A 2 mL dose of 5 mg/mL albuterol sulfate was aerosolised using a vibrating mesh nebuliser
(Aerogen Solo, Aerogen, Ireland) during simulated mechanical ventilation (Servo-U, Maquet, Sweeden)
to examine the effects of ventilator circuit configuration on the delivered dose to an adult (Vt 500 mL,
15 BPM, I:E 1:1) tracheostomy patient. The first ventilator circuit arrangement had a humidifier, with
the nebuliser placed on the dry side of the humidifier within the dual limb circuit (RT200, Fisher &
Paykel, New Zealand), and the second circuit had a HME (Inter-Therm filtro HME, Intersurgical),
attached between the patient side of the wye and the tracheostomy tube (TT) (adult ID 6.4 mm, Shiley,
Medtronic, Ireland). A capture filter (Respigard, Baxter, Ireland) was placed between the TT and the
artificial lung. The mass of drug delivered was determined using UV spectrophotometry at 276 nm.
Results, indicating the dose delivered to the patient, are expressed as the percentage of the nominal
dose placed in the nebuliser’s medication cup.
Results
The results are shown in the tables below.











Albuterol sulfate (5 g/mL) 4.42 ± 0.25 42.01 ± 1.2 40.86 ± 2.87 0.58 ± 0.01 2.91 ± 0.05
Promixin (5 mg/mL) 5.07 ± 0.39 37.12 ± 1.3 38.47 ± 2.66 0.23 ± 0.01 1.61 ± 0.05
Tobramycin (80 mg/mL) 4.98 ± 0.18 40.11 ± 1.63 38.47 ± 2.32 0.53 ± 0.04 42.64 ± 3.05
Amikacin (2.5 mg/mL) 3.48 ± 0.5 57.07 ± 2.19 46.74 ± 2.77 0.10 ± 0.01 2.52 ± 0.14
Table 2. Effect of ventilator circuit configuration on the efficacy of aerosol delivery.
Therapeutic Circuit Arrangement Lung Dose (%)
Albuterol sulfate (5 mg/mL)
With Humidifier 32.13 ± 1.96
With HME 30.96 ± 0.65
Conclusions
These findings confirm that the majority of the aerosolised particles are within the 1–5 µm inhalable
range to treat ventilator associated infections. Simulated breathing during mechanical ventilation of an
adult tracheostomy patient indicates that ventilator circuit arrangement did not have a statistically
significant effect on the dose delivered to the patient, with 32.13 ± 1.96% of the dose of a tracer
aerosol delivered in an active humidification circuit, and 30.96 ± 0.65% delivered in a typical passive
humidification (HME) circuit under the same breathing parameters (p = 0.206).
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2.8.9. An (Infectious) Year in the Life of an Ecmo Unit
Stephanie Thomas 1, Dr Julian Barker 2 and Ranajoy Sankar Bhattacharya 3
1 Consultant in Microbiology and clinical lead, Wythenshawe Hospital, Manchester University NHS
Foundation Trust
2 Consultant in Critical Care Medicine, Wythenshawe Hospital, Manchester University NHS
Foundation Trust
3 Specialty registrar, Microbiology, Wythenshawe Hospital, Manchester University NHS Foundation Trust
Introduction
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a technique for providing
extracorporeal cardiac and pulmonary support to patients with severe, potentially reversible acute
cardiac or respiratory failure, unresponsive to conventional management. The ECMO circuit bypasses
and defunctions the lungs, reducing the insult caused by mechanical ventilation, whilst maintaining
gas exchange. The cardiothoracic critical care unit in Wythenshawe hospital of Manchester is one of
the five adult ECMO centres in the UK providing service to a wide geographical area in the north-west
of England.
Objectives
Acute respiratory failure secondary to bacterial and viral infections is not uncommon. In previously
healthy individuals these should generally be reversible. However often satisfactory response is not
achieved after invasive respiratory and cardiovascular support along with appropriate antimicrobials
in an intensive care setting. The role of ECMO is well established under these circumstances. However
it needs expensive equipment, highly skilled team of health care professional with round the clock
efficiency. Infections probably are the commonest cause of reversible respiratory failure in in ICUs
however limited data is available from ECMO centres. This assimilation of year -long data from our
unit in Wythenshawe hospital aims to enrich knowledge and collaboration between intensivists and
infection specialists with the view to formulate strategies to prevent and treat infections while on
ECMO support. Physicians already involved in ECMO care in their centres will also be able to reflect
on our findings and observe how this compares with their own data.
Method
Patient data was collected from electronic record including their date of admission, length of stay
and final diagnosis. The day when the patients were initiated on ECMO support was taken as the day
of admission. Some patients had more than on diagnoses. We did not endeavour into looking into the
fact that which of these had been the primary cause for a particular patient being unwell. We have
included the non-infection cases in the analysis as well to demonstrate the wide variety of patients
being served in this centre.
Results
Between April 2018 and April 2019 the unit has managed 27 cases on VV-ECMO majority of them
presenting with respiratory failure secondary to infections. Being a regional centre we accept eligible
patients for ECMO from across the trust and also transfer from neighbouring trust. Generally all the
transfers are agreed in advance with the on call consultant on the unit. About half of the patients
during this period came with influenza with or without complications (Figure 1) and nearly all of
them stayed on ECMO support for more than a week; a third remained on support more than 3 weeks
(Figure 2). Amongst the non-flu patients, all but three had diagnoses of infections in the background,
mainly a variety of pneumonias. There were also two post-surgical and one patient with burn injuries
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who had end up being connected to ECMO support. There has been a seasonal variation in the traffic
of patients and the analysis shows the service being busier during the winter months.Med. Sci. 2020, 8, 13 49 of 52 
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Conclusions
The ECMO unit in Wythenshawe hospital unit has accepted patients for ECMO support throughout
the year but the traffic was disproportionately busy during the winter months. Influenza makes
otherwise healthy people very unwell due to severe respiratory failure reflected on the number of flu
patients managed on ECMO over the period of interest.
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2.8.10. The Introduction of an Intensive Care Sepsis Checklist
Manoj Wickramasinghe
St James’ University Hospital, James Beck
Introduction
Sepsis is a ubiquitous condition within critical care that is associated with high morbidity and
mortality1. There is an abundance of literature suggesting early identification and management of sepsis
is crucia2—on the back of this the Surviving Sepsis Campaign have made several recommendations3.
Patients with sepsis are often complex with other concomitant pathologies. Therefore, it can be
easy for clinicians to overlook key investigations and management steps for sepsis. There is a wealth of
evidence that suggests the use of checklists within ICU can improve patient care and implementation
of best evidence-based practice4,5. Key sepsis bundles/checklists that have been created include the
Sepsis Six which was later named the BUFALO checklist6.
Within our Intensive Care at St James’ University Hospital (SJUH) in England, we have recognised
that there is a need for a standardised approach to the management of our septic patients. Although
the BUFALO checklist, which is used on the wards, has key components in the management of sepsis,
it does not capture some specifics within ICU—these include the ideal use of vasopressors, cardiac
monitoring, specific investigations such as procalcitonin and the use of steroids for septic shock.
Anecdotally we have noticed that some significant components of sepsis management can be
missed septic patients. We propose to formally evaluate our practice within SJUH and then introduce
an ICU-specific Sepsis Checklist.
Objectives
Evaluate current practice within SJUH
Introduce ICU-specific Sepsis Checklist
Improve investigation and management of patients with sepsis
Method
Prospective data collection for a 4-week period prior to implementation of checklist. Patients
were recognised to have sepsis using the qSOFA criteria7. Data was anonymised and entered into an
excel sheet. The checklist was introduced after the initial 4-week period and highlighted in handover
and also via email to nursing and medical teams. Individual bedside explanation and highlighting of
the checklist was carried out over a 1-week period to nurses. Following this data was collected during
a 6-week period.
Results
• 30 patients identified prior to introduction of checklist
• 36 patients after introduction of checklist
• 70% adherence to use of checklist with patients with sepsis
• Prior to introduction of checklist, use of vasopressors, fluid and antibiotic prescription was good
• Key differences after checklist was implemented included blood cultures, sputum cultures, atypical
pneumonia screen, baseline procalcitonin and HIV (See Table 1 and Figure 1)
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Table 1. Data with and without checklist.
Investigation Without Checklist With Checklist
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Sputum culture 44% 100%
Atypical pneumonia 57% 100%
Procalcitonin 43% 97%
HIV 30% 73%
Urine culture 66% 100%
Steroids 50% 100%
Cardiac monitoring 60% 100%
Conclusions
An ICU-specific Sepsis Checklist has been well received in a tertiary unit in England. We have
observed significant and sustained improvement in sepsis management since the introduction of the
checklist. This reflects a large body of evidence that suggests checklists in ICU improve patient care
and management. There is scope for this checklist to be rolled out across multiple critical care units.
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